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The field of DNA nanotechnology aims to construct artificial nanoscale structures
and functionalized materials from DNA. The rapid development of DNA nan-
otechnology has inspired researchers to develop various DNA-based drug delivery
vehicles. One approach to build complex DNA nanostructures is to use the method
of DNA origami, which is discussed in more detail in this thesis.
This thesis examines the use of a tubular DNA origami as a cellular delivery vehicle
for the transport of Streptavidin-Lucia luciferase enzymes into HEK293 cells in vitro.
The correct folding of the origamis was evaluated using agarose gel electrophoresis
and transmission electron microscopy. The transfection was studied using confocal
microscopy and the activity of the delivered enzymes was detected in the cell lysates
using a bioluminescence assay. These DNA origami-enzyme complexes were also
coated with varying amounts of different cationic block-copolymers, and the effect
of these coatings on the enzyme activity was investigated using the bioluminescence
assay.
According to the results, the DNA origami delivered the enzymes into cells and
the enzymes remained active after transfection. The results also suggest that it is
possible to control the enzyme kinetics of the complexes by varying the amount of
cationic polymers that coat the DNA origamis. However, the enzymes were found
to bind nonspecifically to the origamis, and it remains unclear whether the shape
of the origami contributed to the transfection. The stability and integrity of the
complexes should be studied more carefully.
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DNA-nanoteknologia tarkoittaa keinotekoisten nanomittakaavan rakenteiden ja
funktionaalisten materiaalien muodostamista DNA:sta. DNA-nanorakenteiden no-
pea kehitys on innostanut tutkijoita kehittämään niistä erilaisia lääkeainekuljettimia
kohdennettuun lääkeannosteluun. Monimutkaisia DNA-rakenteita voidaan muodos-
taa muun muuassa DNA-origami-tekniikalla, jota käsitellään tässä diplomityössä
tarkemmin.
Tässä diplomityössä tutkitaan putkimaisen DNA-origamin soveltuvuutta kuljettaa
Streptavidin-Lucia luciferase -entsyymejä HEK293-solujen sisään in vitro. Trans-
fektiota tutkittiin konfokaalimikroskoopilla, ja entsyymien aktiivisuutta solujen ly-
saateissa tarkasteltiin mittaamalla bioluminesenssia. Nämä DNA-origami-entsyymi-
kompleksit päällystettiin myös kolmella erilaisella kationisella blokkipolymeerilla.
Polymeeripeitteiden vaikutusta entsyymin aktiivisuuteen tutkittiin mittaamalla
bioluminesenssia.
Tulosten perusteella DNA-origamia voidaan käyttää kuljettamaan entsyymit so-
lun sisään, ja entsyymit säilyttivät aktiivisuutensa transfektion jälkeen. Lisäksi
kompleksin entsyymikinetiikkaa voidaan mahdollisesti kontrolloida säätämällä po-
lymeerien määrää päällysteessä. Entsyymi ei kuitenkaan sitoutunut spesifisesti
origamiin, ja origamin muoto ei näyttänyt vaikuttavan transfektion tehokkuuteen.
Kompleksin stabiilisuutta ja eheyttä on tutkittava tarkemmin.
Avainsanat: DNA-origami, DNA-nanoteknologia, lääkeainekuljetin, Streptavidin-
Lucia luciferase -entsyymi, in vitro
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1 Introduction
DNA nanotechnology is a rapidly growing research field whose aim is to construct
nanoscale structures and functionalized materials from DNA. This has broadened the
concept of DNA and today it is not only a biomolecule that carries genetic information.
The field of DNA nanotechnology was pioneered in 1982 by Nadrian Seeman who
designed rigid branched DNA motifs based on the complementary Watson-Crick base
pairing [1]. Since then, the field has grown significantly and various complex artificial
two- and three-dimensional (2D and 3D) DNA nanostructures have been fabricated
for different functions and applications. Figure 1 illustrates the development of DNA
nanostructures from linear one-dimensional structures to more complex nanometer-
scale objects. One of the most common method to fabricate DNA nanostructures is
known as a scaffolded DNA origami. In this method, a long viral single-stranded DNA
is folded into a desired shape with the help of short synthetic oligonucleotides. DNA
nanostructures have been studied for various applications, including nanoelectronics,
single-molecular recognition, analyze of chemical processes and medical applications.
Figure 1: The interest towards structural DNA nanotechnology has grown enormously
in recent years. Various self-assembled 2D and 3D DNA nanostructures have been
developed for multiple functions. [2]
The development of DNA nanotechnology offers new possibilities for developing
drug delivery nanocarriers. Drug delivery systems have been developed to protect
drugs from degradation in physiological environments and reduce their side effects by
improving their targeting efficiency to specific cells. The current clinically approved
2nanotechnology drug delivery systems are quite simple. Therefore, nanocarriers with
more complex properties, such as cell targeting and triggered drug release properties,
are needed. Various drug delivery systems have already been demonstrated using
organic nanomaterials, such as liposomes and cationic dendric polymers, or inorganic
nanomaterials, such as gold nanoparticles and carbon nanomaterials. However,
these nanomaterials can be toxic when implanted. [3] Instead, DNA nanostructures
are purely biomolecules, which makes them biocompatible with biosystems. DNA
nanotechnology enables control over size, shape and functionality of drug delivery
systems. Especially a DNA origami is a promising candidate to be used as a
nanocarrier, since its folding process is simple and any desired functionality can be
added to it with nanometer precision. In the future, these DNA origami nanocarriers
could be possibly utilized in various therapeutic applications, e.g., cancer therapy,
prodrug medication and enzyme replacement therapy. [4]
The aim of this thesis is to use a DNA origami nanocarrier for the delivery of
active enzymes into cells in vitro. Various DNA structures loaded with specific
molecules have been managed to deliver into cells in vitro and in vivo. However,
only a few studies that concentrate on the activity of enzymes in cells have been
published [5]. Therefore, this thesis also examines the ability of enzymes to retain
their activity after transfection into cells. In addition, the origami nanocarriers were
coated with various polymers, and the effect of these coatings on the enzyme activity
is investigated.
Chapters 2–4 form the theoretical part of this thesis. First, the structure and
properties of DNA are described for facilitating the understanding of DNA origami
construction. One of the most important properties for drug delivery systems are
biocompatibility and biodegradation, therefore these properties of DNA are discussed
in more detail. Chapter 3 provides an overview of DNA origamis. Folding method
of DNA origami and some examples of single-layer and multi-layer origamis are
presented. In addition, the possible applications of origamis are discussed. Chapter
4 focuses on DNA origamis as cellular delivery vehicles. Chapter 5 describes the
materials and methods required for the fabrication of DNA origami nanocarries
loaded with enzymes. Chapter 6 presents the results from the transfection studies
and the enzyme activity measurements that were performed using a bioluminescence
assay.
32 DNA nanostructures
Deoxyribonucleic acid (DNA) has gained a great attention as a building material
because of its distinctive properties. The most important property is the highly
recognition between two complementary DNA nucleotides due to the Watson-Crick
base pairing. The second property is that the nanoscale structure of DNA is well-
understood, therefore the rigidity and flexibility of DNA can be easily tailored. The
second property is that DNA can be easily synthesized, modified and replicated. The
final property is that DNA is a nontoxic and biocompatible material, which makes it
suitable for a wide range of applications. [6, 7] In this chapter, the structure and
properties of DNA are discussed in more detail.
2.1 Structural properies of DNA
DNA is a biopolymer build from deoxyribonucleotide units. Each nucleotide is
composed of a phosphate-deoxyribose backbone and a nitrogenous base, as can be
seen in Figure 2a. DNA contains four different bases: adenine (A), guanine (G),
cytosine (C) and thymine (T). These bases are derivates of purine or pyrimidine.
Deoxyriboses are sugars that are linked together by phosphate groups that form a
phosphodiester bridge between the 3’-hydroxyl of the sugar of one nucleotide and
the 5’-hydroxyl of the adjacent sugar. The base sequence is written in the 5’ → 3’
direction. The structure of a base bonded to a sugar is called nucleoside, whereas
nucleotide is a phosphate ester of a nucleoside. A DNA chain is polar because of
5’-OH and 3’-OH groups in the end of the chain. [8, pp. 74–83] In addition, DNA
chain possess a negative charge, since the phosphate groups (PO−4 ) in the backbone
are negatively charged [9, pp. 11].
DNAmolecules can be single-stranded (ssDNA) or double-stranded (dsDNA). Two
complementary ssDNA strands can be joined together by hydrogen bonds between
pairs of bases, thus forming a dsDNA double helix structure. The structure of a
double-helical DNA is shown in Figure 2b. The base paring follows the Watson-Crick
base-paring rule: adenine is always paired with thymine and guanine with cytosine.
[8, pp. 74–83] The attraction between guanine and cytosine is stronger because
guanine forms three hydrogen bonds with cytosine with an energetic stabilization
of hydrogen bonds of about EG−C = 11 kcal/mol, whereas adenine forms only two
with thymine with a stabilization energy of EA−T = 6.0 kcal/mol [10]. For that
reason, the more G-C pairings DNA double helix contains, the more stable it is
against heating and pH change. [8, pp. 86]. The interactions between base pairs
are quite weak in contrast to the covalent bonds, for example the strength between
two carbon atoms is EC−C = 83.1 kcal/mol [9, pp. 273]. Because of relatively weak
interactions between base pairs, the double helix can be denatured into two single
strands by heating or exposure to high pH or low salt concentration. Thus the process
is reversible. [8, pp. 74–83] The Watson-Crick base paring is the most favored type
of interaction between DNA strands because of hydrogen-bonding requirements and
steric factors [6]. In addition to hydrogen bonds, the stability of a double helix
is affected by other interactions, such as base-stacking interactions, electrostatic
4forces and hydrophobic interactions [7, 11]. Base stacking interactions consist of van
der Waals and dipole-dipole interactions between adjacent bases in a double-helical
structure. DNA is soluble in water, which also stabilizes the structure of a helix [12].
(a) (b)
Figure 2: (a) Negatively charged sugar-phosphate backbone with adenine, guanine
and cytosine bases [12]. (b) DNA double helix structure is formed by the Watson-
Crick base pairing rule: adenine is paired with thymine and guanine with cytosine.
Adapted from [6].
Two DNA helical chains are coiled around a same axis and they run in opposite
directions, which signifies that the formed double helix is anti-parallel. The bases are
on the inside of the helix and perpendicular to the main axis, while the phosphate
and deoxyribose units are on the outside of the helix. [8, pp. 74–83] The dimensions
of a DNA double helix are on the nanoscale. The helix has a diameter of about 2
nm and a helical periodicity of 10-10.5 nucleotide pairs per turn that is about 3.5
nm per turn [6, 13]. Usually, the length of a DNA strand is informed in base pairs
(bp). DNA double helices are fairly rigid polymers when their length is below 50
nm that is 150 base pairs. By contrast, single stranded DNA is much more flexible.
Combining these two different strands, it is possible to construct staple motifs with
desired geometry. [6]
DNA can form different kinds of helical structures, including B-DNA, A-DNA
and Z-DNA conformations. B-DNA is the most abundant DNA conformation under
physiological conditions. Its helical chains consist of 10.5 base pairs per full turn
(360◦), whereas the helical periodicity of A-DNA is 11 bp per turn and that of Z-DNA
is 12 bp per turn. B-DNA and A-DNA are right-handed double helices, while Z-DNA
is left-handed as seen in Figure 3. B-DNA can turn to A-DNA due to dehydration.
[8, pp. 815–816] Different base sequences in B-DNA structure influence helical twist,
mechanical ridigity and resistance to bending of a double helix [12]. There are also
other more uncommon conformations, such as triple-stranded DNA and four-stranded
motifs called tetraplexes [14]. In the examples of this thesis, DNA is in conformation
of B-DNA.
5Figure 3: DNA can adopt different conformations, such as A-DNA, B-DNA and
C-DNA. Most of the DNA are in the B-DNA form in physiological conditions. The
color violet and green signify the bases and the backbone of DNA double helix
respectively. [11]
DNA nanostructures form spontaneously via base pairing interactions of comple-
mentary DNA strands in a process called self-assembly. In other words, DNA single
strands can spontaneously hybridize together to form a double helix. The shape and
functions of DNA constructs are encoded in the sequences of the constituent nucleic
acid molecules. Hence, DNA strands are highly programmable structural building
blocks. The simplest DNA constructs can be formed by hybridizing two dsDNA
that have complementary single-stranded extensions (’sticky ends’) at the end of the
helix. In order to achieve more complex structures, branched DNA motifs have been
combined with sticky-ended cohesion. [13] This construction method has been used
to build periodic structures, such as two- and three-dimensional crystals [15, 16].
The four-arm branched DNA molecule is one of the simplest examples of branched
structures [17]. Figure 4 shows a branched four-arm junction that forms a larger
complex with sticky-ended cohesion. Besides crystal structures, DNA can be used to
construct large objects by DNA origami method that is discussed in Chapter 3.
Figure 4: The four-arm branched DNA molecule forms a larger arrangement by
self-assembly. The DNA branched junction consist of four DNA strands with sticky
ends. The complementary sticky ends (e.g., blue and green strands or red and purple
strands) associate together and form a quadrilateral structure.[15]
6Oligonucleotides can be conjugated with a wide variety of materials, including
proteins, dyes, metal nanoparticles or other small biomolecules. For example, DNA
oligonucleotides can be covalently modified with biotin groups which can bind to
streptavidin protein [18]. Functionalization of DNA enables to organize biomolecules
or nanoelectronic and nanophotonic components in a nanoscale precision. Figure
5 shows two-dimensional DNA arrays that is used to organize gold nanoparticles.
Two different triangle shaped motifs are connected with sticky-ends to form a larger
array, and gold nanoparticles with a size of 5 nm or 10 nm are attached to the
structure [19]. It is also possible to construct multifunctional DNA nanostructures,
since different arms of multibranched DNA nanostructures can be decorated with
different functional groups.
Figure 5: The 2D arrays for organizing gold nanoparticles. Two different triangle
motifs are attached by 5 nm or 10 nm nanoparticles. The motifs are assembled to
form a two-dimensional array. [19]
2.2 Biocompatibility and biodegradation of DNA
DNA nanostructures possess a great potential to be used in many biomedical applica-
tions, for example as nanocarriers for drug delivery. For that reason, it is important
to ensure that DNA nanomaterials do not trigger toxic side effects and investigate
the stability of these materials in physiological conditions. Nucleic acids are not
toxic to cells, as they are found naturally in living organisms [20]. Several studies
[21, 22, 23] have shown that DNA nanostuctures, such as DNA tetrahedron and DNA
origami structures, have no effect on cell viability in vitro. For example, triangular
and tubular DNA origami structures did not show any cytotoxicity to cells after 48
h of incubation [22]. Furthermore, DNA nanostructures, such as DNA origami [24]
and DNA tetrahedral nanoparticles [25], have proved to be biocompatible in in vivo
studies. Zhang et al. [24] investigated a triangle-shaped DNA origami as an in vivo
delivery vehicle for cancer therapy. This DNA origami nanocarrier did not induce
observable systemic toxicity in nude mice. In addition, the blood analysis data from
mice treated with DNA origamis for 6 h did not differ from normal values.
DNA is degraded unselectively by nuclease enzymes in vivo [20]. These en-
zymes break up the phosphodiester linkages in the DNA backbone. However, DNA
nanostructures in contrast to DNA have shown to be more resistant to nuclease
7degradation. A DNA tetrahedra structure [26, 21] and DNA origami objects [27]
have proved to degrade slower than a linear DNA structure. Mei et al. [28] revealed
that different DNA origami structures are stable in various cell lysates for at least
12 h at room temperature, in contrast to natural, single- and double-stranded DNA
that were susceptible to degradation after 1 h of incubation. DNA origami structures
maintained also their functionality after exposure to cell lysates. Mei et al. suggested
that the better stability of these DNA origami structures in cell lysates might result
from the rigidity, compact organization and the high negative charge density of the
structure.
Hahn et al. [29] examined whether in vitro tissue culture conditions cause denat-
uration of DNA origami nanostructures. They concluded that physiological cation
concentrations of cell culture medium are too low for keeping DNA structures stable.
The sensitivity to low cation concentrations depends on the design of DNA structures
and time: only one of four tested structures, DNA nanotube, remained stable after
24 h at 37 ◦C. By increasing the cation concentrations of the media, denaturation
of all the tested structures was prevented with only a little impact on cell viability.
In addition, the denaturation of DNA structures is caused by nucleases present in
fetal bovine serum (FSB) used as a medium supplement. Addition of 10 % FBS
to the medium caused great degradation of the structures by 24 h. The activity of
nucleases could be inhibited by using actin protein as an inhibitor in a cell culture
medium. The stability of the DNA structures were analyzed by agarose gel elec-
trophoresis and transmission electron microscopy (TEM). [29] Moreover, Benson et
al. [30] noticed that the structures with more open conformation could withstand
cell culture buffers better than more dense structures. In another study [31], the
stability of DNA nanostructures in live cultured mammalian cells was examined
using fluorescence resonance energy transfer (FRET) analysis. FRET analysis is
sensitive to the distance between a pair of fluorophores labeled on DNA structures.
The study revealed that DNA cages remained intact within the cells for at least 48 h
after transfection. [31]
The stability of oligonucleotides can be enhanced via chemical modifications of
DNA or by covering DNA with lipid bilayers. Recent study [32] has shown that
nuclease resistance can be enhanced by introducing simple chemical modifications to
oligonucleotide ends with hexaethylene glycol and hexanediol groups. Unmodified
and modified DNA strands were used to construct DNA cages, and the stability
of these structures were evaluated in 10 % (v/v) FBS which contains a mixture
of nucleases and proteins. The DNA cage containing end-modifications showed
increased nuclease resistance with the lifetime of 62 h. In addition, this DNA
structure possessed greater stability than its modified components strands alone.
Perrault et al. [33] suggested that stability of oligonucleotides could be enhanced by
encapsulation of DNA nanostuctures by lipid bilayers. This method is inspired by
viruses that maintain structural integrity by encapsulating their genome and protein
capsid shell in lipid envelope. In this study, a wireframe DNA nano-octahedron
(DNO) structure that resembles a viral protein capsid shell was designed and it
was enveloped by PEGylated (polyethylene glycol conjugated) lipid bilayers. The
more lipids were attached to DNA structure, the more protection it provided against
8nuclease enzymes, such as DNase I digestion. Moreover, the injection of encapsulated
DNO and non-encapsulated DNO into mice showed that encapsulation improves the
pharmacokinetics properties of DNO and decreases immune activation. DNA could
also be covered with virus capsid protein (CP) itself, which was found to improve
the delivery of origamis into cells and be biocompatible with cells [34].
93 DNA origamis
A DNA origami method was introduced in 2006 by Paul Rothemund [35]. He
discovered that DNA origami structures could resolve the problems associated with
other methods that use short complementary oligonucleotides to construct large DNA
nanostructures. The problems with the other methods, such as with a multistranded
approach, are due to multiple purification steps of oligonucleotides, low yields of
product and strict stoichiometry control. For that reason, these methods are limited
to construct only simple geometric shapes. [35, 36] In the DNA origami method,
a long single stranded DNA called ’scaffold’ is folded into desired shapes with the
help of multiple short single-strands of DNA called ’staple strands’. Scaffolded DNA
origami method has fewer defects and higher yield than other assembly methods. In
addition, by using DNA origamis more complex nanoscale shapes can be created, and
its dimensions can be precisely controlled. The folding of DNA origamis is also quite
simple and synthesis times are reduced, as there is no need for stoichiometry control
or multiple purification steps of oligonucleotides. [37] DNA origamis can be fold into
a wide variety of structures ranging from simple 2D and 3D lattices to complex 3D
shapes. The structures can be easily functionalized by integrating functional groups
to staple strands, which allows attachment of e.g. chemical groups, biomolecules
or fluorescent dyes to the structure. This enables the use of DNA origamis in a
wide range of applications. DNA origami method and multistranded approach are
compared in Figure 6.
Figure 6: (a) The multistranded approach uses short complementary single strands
to assemble into a branched DNA motif. These motifs can form larger structures
by sticky-ended cohesion. (b) In the DNA origami approach, a long single stranded
scaffold forms base pairs with multiple short single strands, which leads to a desired
shape. [36]
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3.1 Folding of DNA origami
A long single-stranded scaffold is usually taken from the circular M13mp18 bacterio-
phage genome while staple strands are synthetically produced. The M13mp18 scaffold
is about 7000 nucleotides long and it can form structures with tens to hundreds
nanometer dimensions with a molecular weight in the megadalton (MDa) region [38].
It is also possible to use other types of scaffold strands, such as smaller scaffolds [39]
or scaffold strands from double-helical DNA [40]. Typically a few hundred staple
strands are needed to form DNA origami, for example Rothemund used over 200 sta-
ple strands to fold the M13mp18 scaffold into two-dimensional shapes with a spatial
resolution of 6 nm [35]. The length of staple strands can vary from 18 nucleotides to
50 nucleotides. Strands below 18 nucleotides may not be stable at room temperature
and strands over 50 nucleotides may not be sufficiently pure. The long continuous
single-stranded scaffold forms the shape of a desired object. Staple strands bond to
scaffold by the Watson-Crick base pairing, hence scaffold sequences determine the
sequences in the staple strands. In addition to double-helical domains, DNA origami
structures can also contain single-stranded domains which can for example prevent
base-stacking interactions between interfaces or act as an attachment site for other
molecules. [27]
In order to form a desired shape, double-helical domains must be connected to
adjacent double-helical domains by antiparallel interhelix cross-overs. These cross-
overs are positions at which strands running along one helix switch to an adjacent
helix and continue running there, as shown in Figure 7a and 7b. The position
of cross-overs depends on the desired packing lattice. 2D and 3D DNA origami
structures have different packing lattice rules that are discussed in more detail in
the next section. The structure of DNA origami and the positions of cross-overs can
be easily designed by using computational tools. The software caDNAno facilitates
designing and analyzing the structure of DNA origami [41]. caDNAno files can be
analyzed by the computational tool called CanDo [27]. It analyzes the shape of
desired object: bending, twisting and rigidity.
(a) (b)
Figure 7: (a) Stable strands (coloured strands) forming cross-overs every 21 base pair
to the adjacent DNA scaffold strand (white strand). (b) Scaffold forms the desired
structure with the help of multiple staple strands. Adapted from [27].
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Staple strands can bind to incorrect places on the scaffold. However, there are
excess amount of staple strands in the reaction solution which can correctly bind
and displace incorrect strands. This is called as a strand invasion. Different staple
strands can also interact with one another but there is no perfect complementary
base-pairing between them as there is with the scaffold and the staple strands. For
that reason, the stoichiometry between staple strands has no importance. The excess
of staple strands also prevents the scaffold from forming secondary structure by itself.
[35]
The first step for building DNA origami objects is to design and analyze the
desired structure with caDNAno and CanDo programs and decide the lattice packing
rule. The design of 3D objects requires more accurate theoretical optimizations than
2D objects. In the folding process, staple strands and a M13mp18 scaffold are mixed
in a fixed stoichiometry with the existence of cations, water and pH stabilizing buffer.
Cations are needed to prevent the negative charge-repulsion forces of the nucleic acid
phosphodiester backbone. Cation concentrations in the reaction solution depend
on the structure of a DNA origami, for example 3D structures require more cations
than 2D structures. The mixture is exposed to a thermal denaturation and annealing
procedure during which the folding of a DNA origami occurs. Denaturation occurs by
heating the mixture to about 70–80 ◦C, and then the mixture is cooled down slowly.
[27] The structure of origamis determines the temperature at which DNA origamis
are folded. Multilayer DNA objects are detected to fold at temperatures between
45–60 ◦C [42]. Single-layer objects can self-assemble within few hours. Multilayer
objects usually require several days to self-assemble but complex objects have also
been succeeded to fold in less than an hour [42]. The assembly reaction conditions
should reach a minimum energy state when the target structure is self-assembled.
After the folding, DNA origami objects are purified from the excess staples.
Purification methods include ultrafiltration, gel filtration with spin colums, agarose
gel extraction, poly(ethylene glycol) (PEG) precipitation or ultracentrifugation [43].
The selection of the most suitable purification method depends on the functional
groups attached to origamis and the target application. The quality of folding and
purification of DNA origamis can be detected by agarose gel electrophoresis. DNA
origamis can be imaged with atomic force microscopy (AFM) and negative-stain or
cryogenic transmission electron microscopy (TEM).
3.1.1 Single-layer DNA origami
One of the first examples of single-layer origamis were Rothemund’s star, smiley face,
rectangle and triangle origamis with a diameter of about 100 nm [35], as shown in
Figure 8. These structures are synthesized in less than two hours and the highest
yield obtained was 90 %. In order to achieve planar structures, cross-overs in one
helix should occur every 1.5 helical turns (16 bp) to two adjacent double-helices,
which means that the interhelical connections are formed every 180◦ along alternating
sides of a helix.
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Figure 8: Single-layer DNA origami shapes: (a) star (b) smiley face (c) rectangle
(d) triangle. Top row presents the scaffold routing. Second row shows the base-pair
index along the folding path: red is the 1st base and purple the 7000th. Bottom row
shows AFM images of the structures. [44]
The length of the scaffold determines the size of a DNA origami object. For that
reason, various methods have been developed to construct larger 2D structures. One
method to assemble larger structures is to use more complex staples. Zao et al. [45]
scaled up the size of 2D DNA origami by using nine rectangular-shaped DNA tiles as
staple strands instead of short oligonucleotides. They compared the size of origamis
built from staple tiles with origamis built from short staple strands. A segment of
M13mp18 scaffold of the same length was used to fold these origamis. The results
showed that with staple tiles the size of the 2D DNA origami was increased from 34
nm x 28 nm to 54 nm x 70 nm. It is also possible to use DNA origamis as single tiles
to fold a scaffold strand. This is called as an origami of origami or a superorigami.
[45] In other study, Zao et al. [46] managed to create different superorigami structures
from DNA origami tiles folded with pre-formed scaffold frames. These structures
could broaden the size of origamis to micrometer scale. Another method to expand
the size is to use double-stranded genomes as scaffolds. Yang et al. [47] used double-
stranded DNA scaffold to fabricate DNA origami triangular structure that contains
both of the constituent ssDNA molecules. The edges of the triangular structure
fabricated were 215 nm. It is much larger than the maximum area and volume of
an M13mp18 DNA origami structure that is 78 x 78 nm2 for 2D and 24.7 x 24.7 x
24.7 nm3 for 3D [47]. In addition, larger structures can be created by connecting
individual origami tiles through sticky-ends association [48].
3.1.2 Multilayer DNA origami
Single-layer origamis cannot withstand very well mechanical stress and their structures
are quite simple [36]. As a result, more complex and rigid 3D origamis have been
developed. Douglas et al. [49] were the first to design DNA origami objects with 3D
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structures. They successfully designed six different 3D DNA origami shapes with
dimensions ranging from 10 nm to 100 nm. Since then, various different 3D structures
have been developed, such as a hollow box, tubular and triangular structures and a
nanoflask structure. Figure 9 presents different 3D origami structures.
Two main strategies are used to build three-dimensional DNA origamis. In the
first method, individual single-layer origami sheets are interconnected at the edges
by joint strands to form hollow 3D cages, such as a hollow box as shown in Figure
9a [50]. The second method utilizes cross-overs to interconnect antiparallel helices,
which allows to construct more densely packed structures. The packing rule can be a
honeycomb or square lattice. In the honeycomb lattice, cross-overs are formed every
7 bp, which means the rotation of 240◦ in the helical axis and cross-overs every 21 bp
are formed to the same adjacent strand (Figure 9c). [27] As shown in Figure 9e and
9f, cross-overs that are not formed every 7 bp in the selected array of honeycomb
lattice packing cause twisting of the target object. Moreover, deleting of one base
pair on one side of array and inserting one base pair on the opposite side of array
cause global bending of the helices (Figure 9g). The degree of the curvature could
be fine-tuned by varying the number of insertions and deletions of base pairs. [51]
DNA origami can also be packed into a square lattice. In the square lattice packing,
cross-overs are placed to four nearest neighbor strands, which leads a more dense
structure (Figure 9d) [27].
Various examples of three-dimensional DNA origamis with twisted and curved
structures have been reported. Han et al. [52] designed curved DNA origami structure
with Möbius topology. Möbius strip means a strip with a half-twist that is joined
together at the ends of the strip to form a loop. The strip contained eleven DNA
double helices and it was 210 nm in length and 25–30 nm in width. In the later
study, Han et al. [38] created a method to construct more complex DNA origamis
with curved surfaces (Figure 9b). They succeeded to assemble 2D concentric rings,
3D spherical shells and spheres and nanoflasks. Different curvatures were created
by increasing the number of base pairs between crossovers of the adjacent helices
so that the distance between the crossovers increases from inner to outer circles. In
addition, designing helices with less or more than 10.5 bp per helical turn induced
global twisting.
The mechanical stability of 3D DNA origamis can be improved by tensegrity
structures. Tensegrity is a concept that refers to a discontinuous set of compression
elements that are opposed and balanced by a continuous tensile force. The balance
between the two forces leads to stable and mechanically rigid structures. [36] Liedl
et al. [53] designed a 3D tensegrity prism composed of three compression-resistant
bundles of DNA double helices that was held in place by tensed single-stranded DNA
segments (Figure 9c bottom). They proposed that by using a single-stranded DNA
as a source of tensile force in DNA structures, it could be possible to construct more
flexible and mechanically responsive DNA structures. These structures could be used
to study molecular forces and other biological processes.
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Figure 9: Different kinds of spacing rules and the resulting 2D or 3D structures
of DNA origami. The second column presents the number of base pairs between
cross-overs along the same helical axis. (a-b) shows single-layer and (c-g) multilayer
DNA origami structures. [36]
3.1.3 Scaffold-free "origami" and meshing methods
In addition to scaffolded DNA origamis, scaffold-free designs have also been reported.
In a scaffold-free method, desired 2D or 3D structures are constructed by hundreds of
short synthetic single DNA strands called "tiles" or "bricks". Synthetic single-strands
self-assemble into target structures by forming sticky-ends between different strands,
therefore there is no need for the scaffold strand. Single strands can also be added or
removed independently. [54] Ke et al. [54] constructed a cubic-like molecular canvas
from DNA bricks of 32 nucleotides long with four 8 nucleotide binding domains. The
canvas consists of cubes (voxels) and each voxel represents 8 bp interactions between
bricks. By selecting subset of bricks from this canvas, one can create hundreds of
different lego-like shapes. Figure 10a shows one example of lego-like shapes.
Other complex DNA nanostructures can be created via 3D meshing methods.
Han et al. [55] managed to construct gridiron-like DNA origamis ranging from
2D structures to 3D structures and curved objects as shown in Figure 10b. The
basic components of DNA origami gridirons are a long scaffold strand and four-arm
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junctions built from short DNA strands. In their design, four-arm junctions were
used as vertices and a scaffold strand was required to force the junctions to rotate
and achieve the intended structure. The scaffold strand can travel through vertices
in multiple directions. The shape and size of gridiron structures can be tailored by
varying the length of individual junctions. In other study, Benson et al. [30] designed
an algorithm to construct 3D DNA polygon meshes. The aim of the algorithm is to
find a routing for a scaffold so that the scaffold forms a mesh by traversing the edges
of the mesh only once. Moreover, the algorithm uses staple strands to connect the
edges of the mesh as shown in Figure 10c, and it calculates also the physiological
model in order to obtain more relaxed structure. Designed structures have more loose
structure than conventional DNA origami structures that are built from close-packed
helices. Benson et al. suggested that their method might enable rapid 3D printing at
the nanoscale because of its highly automated design process.
Figure 10: (a) Scaffold-free origami design. (b) and (c) 3D meshing methods to
create complex DNA nanostructures. Adapted from [4].
3.2 Applications
One of the most important properties of DNA origami are the easiness of chemical
modifications to its structure and the precise spatial control of functionalities attached
to it. As a result, DNA origami nanostructures have gained a lot of interest in a
wide range of applications. These applications include for example single-molecular
recognition and arrangement, analyze of chemical and biochemical processes, na-
noelectronics, molecular imaging and medical applications, including drug delivery
systems and other complex tasks in cells. DNA origami-based drug delivery systems
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are discussed in more detail in Chapter 4, while this chapter focuses on the other
interesting applications of DNA origamis.
Since various techniques have been developed to chemically modify DNA oligomers,
almost every functional group can be attached to DNA origami structures. Func-
tionalization of DNA origamis can be attained by the hybridization of a modified
DNA oligomer with a receptor connected to a staple strand or by directly using a
modified DNA strand as a staple strand [56]. DNA origami structures have been
conjugated with metal nanoparticles, carbon nanotubes, quantum dots and virus
capsids, for instance [44]. One widely used chemical modification is the biotinylation
of staple strands, which allows streptavin or avidin molecules to bind to the origami
structure at selected positions. Biotin binding to avidin protein is one of the strongest
known noncovalent interaction. The biotin-avidin interaction in origami structures
enables conjugation of other biotinylated molecules with DNA origami, for example
biotin-streptavin interaction has been used for the assembly of proteins on the origami
surface [57]. As staple strands can be easily functionalized and they have an unique
position within the origami structure, DNA origamis are promising platforms for
arranging and recognizing objects with nanometer scale precision. For example, a
nanoparticle-conjugated staple strand can hybridize with M13mp18 scaffold that
position the conjugate to the target place [44]. Functionalities placed on the surface
of 2D DNA origami can act as a probe for molecular recognition [58].
One of the first examples of molecular recognition using DNA origamis was the
label-free detection of messenger RNA (mRNA) [59]. The DNA origami structure
contained probe strands that were 20 nucleotides long single-stranded DNA segments.
These probe strands selectively bound to the RNA targets. Three different probe
strands were used to recognize mRNAs corresponding to regions of three different
genes: Rag-1, C-myc or β-actin. It was noticed that the position of the probe affects
target binding. According to this study, DNA origami may be used as a detector for
gene expression at a single-molecular level. [59] Since then, DNA origami has been
used for detection of many other molecules, for example it could be possible to detect
single-nucleotide polymorphism [60] or conformational changes in DNA [61]. The
single-nucleotide changes in the DNA code is the basis of genetic variation, and it can
protect or alter some individuals to deseases, such as cancer or diabetes. Moreover,
DNA origami method can be used for investigating the effect of the distance between
adjacent probes on binding of the target substance, such as aptamer binding to
protein [62].
DNA origami has also shown a great potential in studying dynamic processes, such
as enzymatic reactions and molecular dynamics. Chemical reactions can be precisely
controlled and optimized by the spatial arrangement of components. Chemical
components could be arranged close to each other with DNA origami in order
to fasten reaction rates, as illustrated in Figure 11a. DNA origami could also
artificially direct enzyme cascade reactions by choosing the correct stoichiometry,
and thus improving reaction flux. Three-dimensional DNA origamis could also mimic
the closed enzyme assemblies in which components could be encapsulated by the
origami structure (Figure 11b). Such systems could prevent diffusive loss of reaction
intermediates to the bulk. Another possible approach to prevent loss by diffusion
17
is to use DNA-based motors to transport molecular components between reaction
centers. With these properties DNA origamis could serve as nanofactories in future
applications (Figure 11c). [63]
Figure 11: DNA origami (in grey) for controlling chemical reactions. (a) DNA origami
could precisely control the placement of reactants to increase the reaction rate. (b)
DNA origami could also encapsulate reactants to avoid diffusion of intermediates.
(c) DNA origami-based nanofactory for performing several tasks. DNA walkers (in
black) could transport reactants between reaction centers.[63]
DNA-based nanodevices that control chemical synthesis have also been reported.
Gu et al. [64] presented a DNA-based assembly line that uses a DNA walker to
fabricate different objects from gold nanoparticles. A DNA origami was used as a
framework to which cargo-donating devices were attached. A triangle-shaped DNA
walker with single-stranded DNA segments as hands and feet moved from device
to device on the DNA framework and collected the gold nanoparticle cargoes. The
cargoes and the devices were encoded with appropriate DNA sequences in order
to the walker to recognize the correct attachment sides. DNA origami structures
could also be used to investigate the properties of motor protein ensembles. Derr
et al. [65] designed 3D DNA origami template with specific binding sites for motor
proteins. The number of attachment sites for the proteins was demonstrated to affect
the velocity of a single protein. They also noticed that the binding ability of a motor
protein was dependent on the presence and number of other motor proteins. [65].
DNA origami-based hybrid materials have gained a great interest as a component
in nanoelectronics, because they can arrange metal nanoparticles and other inorganic
materials. Hybrid materials consist of two or more different constituents at nanometer
or molecular level. The metallization of DNA with gold, silver, copper or nickel enables
the formation of conductive elements for nanocircuits. However, the metallization
of DNA origami presents several challenges, including the stability of the origami
during metallization and more difficult surface adhesion due to the small size of
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DNA origami. [66] For the potential use in nanocircuits, it is important to be able to
precisely control the position and orientation of origami templates [44]. Hung et al.
[67] combined top-down lithography and bottom-up DNA self-assembly to arrange
5-nm gold nanoparticles. The arrangement of these nanoparticles is not possible
with conventional lithography methods, since only about 100 nm patterns can be
obtained. AFM images (Figure 12) showed that gold nanoparticles attached to the
corners of the triangular DNA structure that was bound selectively on the patterned
silicon oxide surface of the substrate. The binding was performed by lithographic
patterning in which negatively charged origami structures bound to hydrophilic
patterns on hydrophobic surface. [67] Moreover, the position of origamis could be
controlled by a dynamic dielectrophoresis [68]. Maune et al. [69] demonstrated also
that DNA origamis can be used to organize single-wallet carbon nanotubes that have
great electronic properties. Another study showed that the arrangement of metal
nanoparticles by DNA origami can lead to chiral plasmonic structures with optical
activity [70].
Figure 12: The adsorbed origami structures were imaged by AFM [67]. The left figure
demonstrates the control over the position and orientation of triangular DNA origami
templates by lithography patterning. The right image shows gold nanoparticles that
were attached to the corners of origami templates. Figure from Ref [44].
DNA origami could also be used as a ruler to measure distances between single
molecules, such as fluorescence dyes, and to calibrate superresolution microscopic
techniques [71] that can be used in imaging objects below the diffraction limit of light
of about 200 nm. Moreover, DNA origami is a promising platform for controlling the
position of multiplexed fluorescent tags, therefore it could be used as in situ imaging
probes for fluorescence microscopy [72]. Another possible application includes DNA
origami for determination of the structure of membrane protein by nuclear magnetic
resonance (NMR)[73].
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4 Cellular delivery vehicles
DNA nanostructures are promising candidates to be used as nanocarriers in drug
delivery systems for various therapeutic applications. As a result, multiple promising
examples of DNA origamis and other DNA-based nanomaterials as nanocarriers have
been reported, however it must be emphasized that the development of DNA delivery
vehicles is in its early stage. In this chapter, the properties of DNA nanostructures
that meet the most important requirements for delivery vehicles are discussed. In
addition, several DNA-based nanocarrier systems are presented in order to understand
the versatility of DNA as a nanocarrier for various cargoes. The final section describes
more closely three potential therapeutic applications for DNA-based delivery vehicles
that are enzyme replacement therapy, prodrug medication and anticancer therapy.
4.1 Requirements for delivery systems
Several requirements must be taken into account when designing cellular delivery
vehicles. First of all, delivery vehicles must be biocompatible in cellular environment
and biodegradable to minimize the risk of toxicity. Delivery systems should be
able to be loaded with cargoes and protect them from chemical and enzymatic
degradation. They must also remain stable in cellular environment until entering
cells and releasing their cargoes. Highly desired properties also include the release
of drugs in a controlled manner and selective recognition of target cells to achieve
appropriate circulation times and to avoid side effects. [74, 20] Figure 13 illustrates
some obstacles that delivery vehicles must overcome to obtain therapeutic effects.
Cellular environment affects the stability and the diffusion of DNA nanostructures.
As a biological material, DNA nanostructures are biocompatible and biodegradable
in cellular environments. However, several studies have demonstrated that DNA
nanostructures can remain stable in cell culture media for 24 h [29] and even in cells
for about 48 hours [31]. The stability and biocompatibility of DNA were already
discussed in more detail in Chapter 2.2.
Nanocarriers should possess high loading capacity of cargoes, and their size should
be precisely controlled. DNA nanomaterials can be designed into various architectures
with a predictable and well-defined structure, which enables optimizing a variety of
parameters for cellular delivery. For example, the position and spatial orientation of
cargo molecules can be precisely controlled by DNA origamis. Various methods can
be used for functionalization of DNA, including covalent modifications, biotin-avidin
interaction, encapsulation of molecules into DNA structures and intercalation of
molecules between planar bases of DNA. DNA constructs also enables multiple
therapeutic molecules to be simultaneously incorporated and delivered, for example
DNA nanostructures could be loaded with targeting ligands, anticancer drugs and
therapeutic oligonucleotides [75]. The structures can also contain fluorescent dyes for
detecting the targets. In addition, the density of conjugated molecules on the surface
of DNA nanostructures can be well defined. [3] The density of surface molecules
as well as the biophysicochemical properties of the vehicle, such as size, shape and
charge, can effect on the circulation life and biodistribution of cargoes [76].
20
Figure 13: Some requirements that delivery systems must overcome to achieve
therapeutic effects. These include long circulation time, active targeting, the ability
to enter cells, to release of cargoes in a controlled manner and to escape from
endosomes. [74]
Cellular delivery vehicles must also be able to enter cells through the cell membrane,
either by passive or active uptake. Important factors for cellular uptake of nanocarriers
is the particle size and surface properties. Particles with the size of tens to hundreds
of nanometers have been shown to enter cells more effectively than individual small
molecules [20]. The surface charge of nanoparticles affects the transfection efficiency,
since the cell membrane possess a negative charge. Nanocarriers with a positively
charge surface generally enter cells easier. Although bare nucleic acids are highly
negatively charged molecules that are difficult to pass through the membrane, DNA
nanostructures have been showed to penetrate the negatively charged cell membrane.
[3, 77] Usually transfection reagents, such as cationic lipids and polymers, are needed
to enhance intracellular uptake of nucleic acids, although these reagents can be
cytotoxic to living cells. One of the most used transfection reagent is lipid-based
transfection agent Lipofectamine®. However, some DNA nanostructures have been
showed to enter cultured cells without the help of any transfection reagent, for
example a tetrahedral DNA nanostructure alone was capable of entering cultured
mammalian cells [31, 78]. The cellular uptake of DNA nanocarriers is mainly studied
by fluorescence-based assays, e.g., confocal microscopy and flow cytometry. However,
fluorescent labels may in some cases affect the assembly or cellular interactions of
DNA nanostructures. One alternative method for quantification of cellular uptake of
DNA origamis is quantitative polymerase chain reaction (qPCR). qPCR is used to
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amplify and quantify DNA molecules in solution, therefore it could also be employed
to quantify the M13mp18 scaffold of DNA origamis in cell lysates. [79]
Furthermore, cellular uptake mechanisms of drug loading carriers affect the drug
efficiency. It is still unclear by which mechanism DNA nanostructures penetrate into
cells. Possible active cellular uptake mechanisms for nanocarriers include phagocytosis
or other endocytosis pathways, especially receptor-mediated endocytosis [77]. In the
endocytosis pathways, cell membranes transports particles into the cell by forming a
vesicle around the particles. The transported cargoes must be also able to escape
from these endosomes [74].
Although various DNA nanostructures, such as DNA cages [31], DNA pyra-
mids [78] and DNA nanotubes [80], have been reported to enter cells, the efficient
transfection of DNA constructs is still challenging. Therefore, new approaches are
needed for enhancing the cellular uptake of DNA nanomaterials. One approach is
to encapsulate nucleic acids with virus capsid proteins. Mikkilä et al. [34] utilized
purified cowpea chlorotic mottle virus (CCMV) capsid proteins (CP) as coatings
for rectangular DNA origami structures. These virus capsid proteins can bind on
the origami surface through electrostatic interactions. The morphology of DNA
origami-CP complexes changed from rolled-structures to open tiles while increasing
the fraction of CP, as shown in Figure 15f. In the open tile structure the origamis
were completely encapsulated. According to this study, the cell uptake of DNA
origamis could be raised with increasing CP concentrations. This might support the
assumption that the rigid and compact DNA structures enter cells more efficiently
than the flexible ones [4]. In addition, DNA origami has been encapsulated with
PEGylated lipid membranes (Figure 15g), which were effectively uptaken by immune
cells [33]. Another approach to improve cellular uptake is to modify the surface
properties of DNA origamis using DNA intercalators. The DNA intercalators are
small molecules that can form noncovalent interactions between planar bases of
double-stranded DNA. The DNA origamis modified with intercalators have been
demonstrated to be uptaken by cells more easily than the unmodified origamis [81].
The performance of drugs can be improved by targeted drug delivery and controlled
drug release systems. When drug loading nanocarriers are in the bloodstream, they
must not interfere with the veins or the surrounding tissue but with the target
cells. Therefore, drug delivery vehicles should identify specific receptors at target
cells or contain a logic gate that triggers the drug release at a specific location.
Releasing drugs in a controlled manner reduces the distribution volume of drugs in
vivo, thus decreasing side effects. [20] One common method to identify target cells is
to incorporate specific ligands, such as peptides, aptamers, antibodies or folic acids,
into DNA nanostructures. These ligands bind to receptors found at target cells.
Aptamers are short single-stranded DNA or RNA oligonucleotides that specifically
bind to various molecular targets. They also exhibit significant therapeutic effects.
Incorporation of aptamers into pyramidal DNA nanostructures showed an enhanced
intracellular uptake and selectively inhibit the growth of cancer cells [78]. These
DNA pyramids contained multiple overhangs to which targeting ligands, aptamers,
could attach, as shown in Figure 14. Another specific ligand, folic acid, binds to
folate receptors that are selective tumor markers located in many cancer cells. In
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one study, folate molecules were incorporated into DNA nanostructures for targeted
delivery of siRNA to tumor cells [25]. These folic acid-conjugated nanostructures
showed the greatest targeting efficiency among various cancer-targeting ligands.
Figure 14: Aptamers used as targeting ligands. Three overhangs in the DNA pyramid
allow attachment of aptamers to the nanostructure. [78]
DNA nanostructures are potential delivery vehicles for controlled drug release,
since it is possible to design DNA nanostructures that can change conformation in
response to sensing external signals in the environment [50, 82, 83]. One possible
controlled drug release system is a box shaped DNA origami structure with a lid
that can be opened to the response of specific oligonucleotide sequences used as
’keys’ (Figure 15a) [50]. These DNA boxes could be used as nanocarriers with the
potential to respond to particular biomolecular signals in cells. Another designed
nanocarrier for controlled release of cargoes contained an aptamer-encoded logic gate
(Figure 15e) [82]. The system could be locked using two similar aptamers or using
two aptamers that are specific to two different targets. The gate opened only if the
both aptamers recognized their targets simultaneously. Furthermore, a tweezer-like
DNA nanostructure has been reported to be able to regulate its binding affinity
with a protein in a distance-dependent manner [84]. This nanostructure could bind
to the target protein when two ligands are located at an appropriate distance and
that is referred to a closed state. However, the protein could be released in response
to specific strand that increase the distance of the two ligands leading to an open
state. This capture-release cycle could be repeated several times without changing
the ligands and the target protein.
4.2 DNA origami and other DNA nanostructures as nanocar-
riers
Various hollow DNA origami constructs have been developed, as shown in Figure 15a.
These hollow DNA constructs could be used to deliver cargoes into cells and protect
cargoes from degradation in cellular environment. Ke et al. [85] designed a closed
DNA tetrahedron with an inside cavity that could potentially used for encapsulating
cargoes. Box-shaped DNA origamis have also been designed for the same intention
[86, 50].
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As discussed in the previous section, various DNA nanostructures are able to enter
to cells. This has inspired researchers to develop DNA nanocarriers for delivering a
wide range of molecules including doxorubicin, siRNA, CpG sequences and antibodies.
One of the most used model molecules for cellular delivery are fluorescent dyes
which can be used for confirming the cellular uptake of DNA delivery vehicles using
fluorescent microscopes.
Doxorubicin (Dox) is a potent anticancer drug that can intercalate the DNA
duplex and inhibit macromolecular biosynthesis. However, free Dox causes side
effects and has poor selectivity. Zhao et al. [87] developed tubular DNA origami
nanocarriers with different degrees of twist that enables regulating the release of Dox
in vitro (Figure 15b). This delivery system was capable of entering breast cancer
cells and inducing cell death. In another study, Jiang et al. [22] managed to deliver
doxorubicin not only into regular human breast adenocarcinoma cancer (MCF 7) cells
but also into Dox-resistant cancer cells using triangular- and tubular-shaped DNA
origami structures shown in Figure 15b. The DNA origami nanocarrier enhanced cell
death of resistant MCF7 cells. In addition, doxorubicin has been delivered into cells
in vivo using triangle-shaped DNA origami nanocarriers [24]. This delivery system
examined by fluorescence imaging showed enhanced tumor targeting and long-lasting
tumor accumulation without observable systemic toxicity in nude mice in comparison
to Dox alone. These presented DNA origami nanocarriers could serve as potential
delivery systems for anticancer therapy. DNA origamis seem to possess various
advantages as antitumor drug carriers compared with other DNA nanostructures
such as wireframe cages. For example, DNA origamis could load more doxorubicin
than the DNA nanocages. Furthermore, DNA origami can be designed in sizes
ranging from ten to several hundred nanometers with controlled three-dimensional
geometry, while the size of DNA cages can only vary between approximately 7–20
nm. [24]
Moreover, various DNA-based assemblies could be used for controlled and targeted
release of Dox. For example, the cellular delivery of Dox for cancer therapy could
be enhanced by multifunctional aptamer-based DNA nanoassembly [75], shown in
Figure 15h. As discussed earlier, aptamers can be used to guide delivery vehicles to
target cells. DNA-based multilayer nanofilms have also been reported to release Dox
in a controlled way in serum conditions [83]. The nanofilms consisted of homopolymer
as a template and three-dimensional DNA origami structures with Dox incorporated
to it. The electrostatic interaction between the positively charged homopolymer and
the negatively charged DNA was modulated by the change in pH conditions, which
led to the release of some of the Dox-incorporated DNAs from the film. The release
profile of Dox was dependent on the properties and shapes of the 3D DNA structures.
The structure of the nanofilms can be seen in Figure 15h.
Apart from aptamers, DNA nanocarriers could also be loaded with various other
functional nucleic acids, including antisense oligonucleotides, small interfering RNAs
(siRNAs) and microRNA, that have high potential for diagnostic and therapeutic
purposes [3]. siRNAs are chemically synthesized RNA sequences that can bind
complementary mRNA molecules and inhibit them from synthesizing proteins. DNA
nanostructures can be utilized for delivering siRNAs into cells in order to prevent
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the expression of a certain gene that causes disease. Nanocarriers are also used to
improve the cellular uptake and the stability of siRNA against enzymatic degradation.
Kocabey et al. [88] investigated the ability of folate-modified DNA nanotubes loaded
with siRNAs to silence a target gene. DNA nanotubes were capable to enter cells but
they did not succeed in gene silencing. The structure of the DNA nanotube is shown
in Figure 15c. However, Lee et al. [25] managed to create gene silencing system that
used DNA tetrahedral nanostructures with folate and peptide targeting for siRNA
delivery to tumor cells in vitro. Figure 15c shows the DNA tedrahedron structure
with siRNA molecules hybridized to it and modified with tumor targeting ligands.
The gene silencing efficiency was noticed to depend on the spatial orientation and
the density of the ligands.
In addition to anticancer therapeutic and gene silencing delivery systems, DNA
nanostructures could be utilized as potential immunotherapeutic carriers. When
DNA nanocarriers are loaded with unmethylated cytosine-phosphate-guanosine (CpG)
oligonucleotides, they can induce immune responses in order to protect body from
harmful substances. CpG-DNA complexes could serve as therapeutic agents against
a wide range of diseases such as cancer and allergic diseases. DNA nanostructures
could be used to protect these CpG sequences from degradation and enhance both
cellular uptake and specific targeting of CpG sequences. Schüller et al. [23] used
a tubular DNA origami structure covered with tens of CpG sequences to induce
immune responses in spleen cells (Figure 15d). These origami tubes showed greater
immunostimulatory effects than the same amount of CpG sequences loaded to a
standard transfection reagent (Lipofectamine) system. The DNA tubes did not show
any detectable toxicity in contrast to Lipofactamine. In addition, Mohri et al. [89]
designed a branched DNA structure using oligodeoxynucleotides containing CpG
motifs (Figure 15d) that induced immune stimulatory activity in macrophage-like
RAW264.7 cells. It was noticed that the more branched structure increased the
cellular uptake and immune stimulatory activity but reduced the thermal stability.
A DNA tetrahedron nanostructure has also been used as a nanocarrier for CpG and
shown to efficiently enter RAW264.7 cells without the aid of transfection agents [21].
Furthermore, Sellner et al. [90] managed to induce immune response in muscle tissue
of mice in vivo by using CpG-decorated DNA nanotubes. Importantly, neither plain
DNA nanotubes nor CpG-sequences caused inflammatory effects in the muscle tissue,
which was investigated by fluorescence and transillumination microscopy.
DNA nanostructures could also be loaded with a variety of peptides and proteins
such as antibodies and enzymes. Such nanocarrier systems are highly desired, since
functional proteins are not capable to enter cells easily due to their instability, large
sizes and charged surfaces [5]. For example, DNA origamis have been loaded with
antibody cargoes that induced growth arrest in leukemia cells (Figure 15e) [82].
Antibodies are molecules that recognize and neutralize antigens found in harmful
agents. In addition, Yan et al. [91] used biotinylated DNA tetrahedral nanostructures
to deliver CpG adjuvants and a model antigen streptavidin, which induced an antibody
response in vivo. Adjuvants are molecules that can modify immune response to
produce more antibodies against harmful substances. This antigen-adjuvant-DNA
complex could be used as a delivery system for synthetic vaccines. Brodin et al. [5]
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demonstrated a DNA-based carrier system for cellular delivery of functional enzymes.
β-galactosidase enzyme served as a protein core and it was modified with a dense shell
of oligonucleotides. This DNA-enzyme complex showed increased cellular uptake
when compared with bare enzymes even using enzyme concentrations as low as
100 pM. DNA-functionalized enzymes retained also their catalytic activity after
transfection.
Figure 15: DNA-based delivery vehicles. (a) A DNA box for controlled release
of cargoes [50] and hollow DNA origami constructs [85, 86] (b) Triangular- and
tubular-shaped DNA nanocarriers for delivering Dox [87, 22] (c) A DNA tedrahedron
[25] and tube [88] modified with folate targeting for delivering siRNA (d) A tubular
DNA origami [23] and and a branched DNA structure [89] as delivery vehicles for
CpG motifs (e) A DNA nanocarrier with an aptamer-encoded logic gate for controlled
release of antibodies [82] (f) Virus-encapsulated DNA origamis as delivery vehicles
[34] (g) A spherical DNA origami encapsulated with PEGylated lipid membranes
[33] (h) An aptamer-based DNA nanoassembly for cellular delivery of Dox [75] and
DNA-based multilayer nanofilm for controlled release of Dox in serum conditions
[83]. Figure from Ref [4].
DNA nanostructures not only serve as potential carrier systems for cellular delivery
but also they can act as molecular devices in living systems [4]. DNA templates
can be used for directing protein assembly and functionalized DNA nanostructures
could be used to recognize target proteins. DNA nanostructures could serve as
scaffolds for precisely positioning proteins and they could be used to control enzymes
that catalyze chemical reactions. As a result, several studies have demonstrated
DNA-based nanoassemblies as enzyme cascade nanoreactors for controlling enzymatic
reactions. Liu et al. [92] designed a tweezer-like DNA nanodevice to actuate the
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activity of enzyme/cofactor pair. The enzyme and cofactor were placed at different
arms of the tweezer, and the activation was regulated by changing the conformation
between open and closed states as shown in Figure 16a. At a closed state the enzyme
and cofactor were brought together for activation. Linko et al. [93] demonstrated
GOx/HRP enzyme cascade reaction inside a DNA origami tube for detecting glucose.
The tube was assembled from two distinct units with either glucose oxidase (GOx)
or horseradish peroxidase (HRP) enzymes attached inside the origami unit, as can
be seen in Figure 16b. They proposed that the tube could be used as a nanoscale
diagnostic tool or for delivering enzymes into cells, that could be exploited, e.g., in
enzyme replacement therapy.
(a) (b)
Figure 16: DNA-based ’nanofactories’ for controlling chemical reactions. (a) A
tweezer-like DNA nanodevice for controlling enzymatic reactions. Fluorescence dyes
Cy3/5 were used to characterize the open and closed states of the tweezer. [92] (b)
The enzyme cascade reaction was demonstrated by attaching HRP and GOx enzymes
inside the DNA origami tube [93].
4.3 Therapeutic applications
Enzyme replacement therapy (ERT) is a potential approach for treating some lyso-
somal storage diseases (LSDs), such as Gaucher disease and Fabry disease. ERT is
currently approved for treating six LSDs [94]. LSD symptoms can greatly vary but
typically they include central nervous system disorders. LSD results from the failure
in the activity of lysosomal enzymes that transport waste materials and foreign
substances into lysosomes, where they are degraded. If one of these enzymes is absent
or presence in too small amounts, the recycling process will be disturbed causing
the waste materials to accumulate within the lysosome and the cell. In enzyme
replacement therapy, lysosomal enzymes can be delivered, e.g., by infusion into the
systemic circulation, to diseased cells where they move to lysosomes. ERT is shown
to treat LSD in certain organs and tissues but the delivery of enzymes into tissue
of central nervous system remains challenging. Therefore, efficient delivery systems,
that are able to transport enzymes to all the organs diseased by LSDs, need to be
developed. [95] DNA nanostructures could serve as potential delivery nanocarriers
for controlled circulation, organ targeting, cell entry and release of lysosomal enzymes.
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A few studies have demonstrated DNA nanostructures as potential delivery vehicles
for enzymes [5, 93].
Prodrugs refer to a biologically inactive derivates of drug molecules that must
undergo enzymatic or chemical transformation in vivo to release the active drug.
Prodrugs are designed to enhance pharmacological properties of drugs, such as
permeability, aqueous solubility, chemical stability and bioavailability that is defined
as a degree and rate at which a drug becomes available at a target organ. In addition,
prodrugs have been used to improve the transport and selectivity of drugs to their
intended target. There are two main classes of prodrugs: carrier-linked prodrugs and
bioprecursor prodrugs. The carrier-linked prodrug is composed of a carrier to which
drugs are covalently linked. The carrier system undergoes transformation and release
the carrier and the drug once they are delivered to the target place. Bioprecursor
prodrugs do not contain a carrier but they are transformed metabolically or chemically
into an active drug. [96] The selectivity of drugs to their intended targets might be
possibly attained by using DNA nanostructures as a part of carrier-linked prodrug.
DNA nanocarriers can be modified to undergo transformations in response to specific
signals causing the release of cargoes [50, 82], which were already discussed in Chapter
4.1.
Furthermore, as mentioned earlier DNA nanostructures could serve as potential
nanocarrier systems for anticancer therapy. Anticancer drugs are used in chemother-
apy to destroy cancer cells. However, these chemotherapeutic drugs have poor
selectivity and therefore they affect both cancer cells and normal cells causing side
effects. The drug selectivity to cancer cells can be enhanced by loading them to
nanocarriers that have shown a more efficient passive tumor-targeting and an accu-
mulation in tumor tissue in comparison to bare anticancer drugs. This phenomenon
is known as enhanced permeability and retention (ERP) effect. Nanocarriers could
be also utilized to encapsulate and deliver poorly soluble anticancer drugs. [97]
Moreover, another approach to improve selectivity is to use prodrug technology in
which anticancer prodrugs could be designed to target specific molecules located in
high concentrations in tumor cells [96]. There are only a few clinically approved
anticancer drug delivery systems that are based on liposome, polymer and protein
carriers [97, 98]. Various other delivery systems are under development. Several stud-
ies have demonstrated that DNA nanostructures could be used to deliver anticancer
therapeutic agents such as doxorubicin, CpG motifs and antibodies into cells, see
Chapter 4.1. The delivery of CpG motifs could serve as immunotherapy for cancer
cells. Moreover, these nanostructures could be modified to selectively bind to cancer
cells, for example aptamers incorporated in DNA nanostructures can be utilized to
target specific cancer cells [75]. In addition, DNA origamis are found to exhibit ERP
effect [24].
4.4 Challenges with DNA nanocarriers
Several challenges must be overcome and various aspects must be studied in more
detail before DNA structures could be used as delivery vehicles in clinical applications.
The properties of DNA nanostructures need to be further studied in vitro and in vivo
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in order to fully understand their behavior in living organisms. Another important
aspect to study is the transportation mechanism of DNA nanomaterials into cells
including their intracellular route and fate and also their pharmacokinetic properties,
i.e., in vivo circulation and distribution. Attention must also be focused on the
selective uptake of DNA nanocarriers by target cells. DNA constructs are shown
to remain stable in cell lysates and culture media at least a day. However, further
research is needed to examine the effect of the structure of DNA constructs on its
stability [99]. In order to improve the circulation time of DNA nanocarriers, they
can be coated for example with virus capsids [34] or lipid bilayers [33]. It is also
important to study how the physical and chemical properties of DNA nanostructures
affect their intracellular behavior. [3, 99]
In addition to these biologically related problems, the high cost and ineffective
production methods of DNA nanostructures limits their use in practical biomedical
applications. The fabrication of 1 g of megadalton-sized DNA origami objects costs
approximately 100,000 dollars [4], while 1 g of polymer materials used as drug
delivery systems can cost less than 1 dollar [99]. The high cost is partly due to
the lack of an efficient purification method for preparing DNA-based asseblies with
high concentrations. New methods are needed for purification and scaling up the
fabrication of DNA origamis in order to reduce the production costs. The field of
DNA nanotechnology is constantly growing and developing. Therefore, it is expected
that the production costs for 1 g of DNA origami will fall to 1,000 dollars in the
next few years if more efficient purification methods and printing techniques for
sequence synthesizing are developed. [4, 100] One approach to solve the purification
problem is to use PEG purification that is based on adding PEG polymers as a
precipitating agent to DNA solutions. The method has shown to efficiently purify
various DNA origami structures from excess staples with high yields. [101] Recently,
the development of high-cell-density bioreactors increased the production of ssDNA
for scaffolded DNA origamis from the micro and milligram scale to the gram scale
per one liter reaction volume [102].
Furthermore, the size of DNA origamis should be extended in order to increase
the amount of payloads [3]. One approach for scaling up the size of DNA origamis
includes forming a DNA origami from multiple origami structures, as discussed in
Chapter 3. Moreover, the traditional scaffold strand from bacteriophage M13mp18
could be replaced by other scaffold strands, for example longer scaffold strands can
be prepared by using polymerase chain reaction (PCR) amplification [103]. Although
the self-assembly of DNA origamis generally results in correct assemblies, larger
and more complex structures can lead to increasing assembly errors with lower
yields. Therefore, it is important to understand the kinetics and thermodynamics of
self-assembly between the components of DNA constructs. [20, 100]
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5 Materials and methods
In this thesis, a DNA origami was used as a nanocarrier for the transfection of
Streptavidin-Lucia luciferase (LUC) enzymes into human embryonic kidney cells
(HEK293 cells) in vitro. The designed DNA origami is a hollow hexagonal tube with
a molecular mass of about 4.5 MDa. The tube contains three biotin-linkers, which
enables three LUC-enzymes to attach to it by the biotin-streptavidin interaction.
Streptavidin-Lucia luciferase is a small enzyme with a molecular mass of 37 kDa.
Luciferases are used in bioluminescence applications, for example Steptavidin-Lucia
enzyme is utilized to detect streptavidin-biotin interactions. This work utilizes the
bioluminescence phenomenon for detection of the activity of the delivered luciferase
enzymes in cell lysates. The detected light is emitted from the reaction between
luciferase enzyme and its coelenterazine based substrate. Figure 17 summarizes the
main aim of this work. In addition, these DNA origami nanocarriers were coated
with three different polymers to study the effect of the coatings on the activity of
the LUC-enzymes attached to the origamis.
LUC
LUC
LUC
Cell Lysis + Luminescence Assay
Transfection
DNA Origami
Loaded With Enzymes
Figure 17: A DNA origami nanocarrier is loaded with three bioluminescence LUC-
enzymes and transfected into cells in vitro. After transfection the cells are lysed
and the activity of transported enzymes is measured from the cell lysates using
coelenterazine-based bioluminescence assay. [104]
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5.1 Preparation of LUC-origami complexes
The structure of the DNA origami, shown in Figure 18, was designed by Linko et al.
[93, 105]. The designed hollow hexagonal tube (HT) has a length of about 30 nm
and a width of about 27–33 nm. The wall thickness is 6–7 nm and the cavity is 14–21
nm wide. The tube contains three biotinylated strands (HTB) for the attachment of
the streptavidin functionalized LUC-enzymes (STV).
Figure 18: The dimensions of a DNA origami unit used as a nanocarrier. The inner
surface of the origami contains three biotinylated strands for the functionalization
of the origami. STVs indicate the positions to which streptavidin functionalized
LUC-enzymes can attach. Adapted from [93].
The DNA origamis were prepared by folding a 7249 bases long single-stranded
DNA scaffold from virus M13mp18 (from Tilibit nanosystems or New England Biolabs)
with a set of short staple strands purchased from Integrated DNA Technologies. As
mentioned above, three of the staple strands contained biotinylated binding sides for
streptavidin functionalization. Moreover, the origamis were labeled with fluorescent
Cy3 tags for transfection studies. The origami contained 5 binding sites for the
fluorescent tags. The overhangs of the binding site strands are complementary to
the Cy3-modified strand, thus enabling a desired attachment. All the staple strands
included in the DNA origami structure are presented in Appendix A. The M13mp18
scaffold strand and the staple strands were mixed with a folding buffer containing 10x
TAE buffer Ultrapure (400 mM tris(hydroxymethyl)aminomethane (Tris), 10 mM
ethylenediaminetetra acetic acid (EDTA) and glacial acetic acid for adjusting the pH
to 8.3, from USB Corporation), magnesium chloride (MgCl2) and sodium chloride
(NaCl). The concentrations of the components needed for folding DNA origamis are
shown in Table 2. The staple strands were added in 10-fold excess concentration to
the scaffold.
The origami solution with the total volume of 100 µl was annealed using G-Storm
G1 Thermal Cycler. The origamis were first heated to 65 ◦C and then cooled down
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to 60 ◦C by 1.0 ◦C decrease in 15 minutes. From 60 ◦C the origamis were cooled
down to 45 ◦C by 0.25 ◦C decrease in 45 minutes after which they were stored at
12 ◦C inside the thermal cycler before the program was stopped. After folding, the
structures were stored at 4 ◦C in the refrigerator.
Table 2: The volumes and concentrations of the components for preparing DNA
origami nanocarriers. Final concentrations signify the concentrations in the origami
reaction solution.
Component Volume Concentration Final Concentration
M13mp18 scaffold 20 µl 100 nM 20 nM
Staples 40 µl 500 nM 200 nM
Folding buffer:
TAE buffer 10 µl 10x 1x
NaCl 10 µl 50 mM 5 mM
MgCl2 20 µl 100 mM 20 mM
The excess amount of staples was removed in a non-destructive spin-filtering
process using Eppendorf Centrifuge 5424R. The spin-filtering process was performed
using Millipore Amicon Ultra 0.5 ml Centrifugal Filters with 100 kDa molecular
weight cut-off. 50 µl of DNA solution was mixed with 450 µl of filtration buffer (5
mM NaCl, 20 mM MgCl2, 1x TAE, pH 8.57) and injected into the filter. The solution
was spun with 14,000 rcf (relative centrifugal force) for 3 minutes at 20 ◦C. Then
flowthrough was discarded and 450 µl of fresh filtration buffer was added to the filter.
The sample was spun in total 4 times repeating the procedure above, expect for the
last round the buffer was changed to HEPES-NaOH (6.5 mM HEPES, pH 6.8) and
the centrifugation time was set to 5 minutes. After the last spinning, the solution
was collected from the filter with a pipette and the filter was turned upside down in
a fresh container and spun 2 minutes at 1,000 rcf to collect the rest of the solution.
After filtration the volume of the solution was typically brought from 500 µl down to
17–24 µl. The theoretical concentration of the origamis before filtering is 20 nM and
after filtering about 40–60 nM if the yield is 100 %.
Streptavidin-Lucia luciferase (LUC) enzyme (100 µg/ml stock solution, from
InvivoGen) was added to origamis in 10–20-fold excess concentration. The solution
was incubated at least 6 h or overnight at room temperature. The excess amount
of added LUC-enzymes was removed by the same filtering method as above. After
filtering the origamis were stored at 4 ◦C. In order to ensure that the filtering
procedure functions efficiently for the LUC-enzymes, the bioluminescence assay was
performed for filtered and unfiltered LUC-enzymes, see Appendix B.
In addition, to be sure that the LUC-enzymes function properly, the biolumines-
cence assay was performed for the free LUC-enzymes. The bioluminescence intensity
of Streptavidin-Lucia enzyme was measured as a function of time by mixing 10 µl of
pure LUC-enzyme (100 µg/ml) with ready 50 µl of coelenterazine-based luminescence
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assay reagent (QUANTI-Luc, InvivoGen). As a blank, 10 µl of autoclaved water was
used and mixed with the reagent. The bioluminescence was immediately detected
after the mixing by using a luminometer (BioTek Cytation 3). The first data points
were recorded 10 seconds after adding the reagent. The same luminometer is used in
all bioluminescence measurements in this thesis. The luminescence decay shown in
Figure 19 demonstrates that the reaction is very fast. Therefore, in each measurement
only the luminescence decay is monitored. The luminescence decay corresponded to
the typical signal produced by coelenterazine-based substrate (InvivoGen).
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Figure 19: The luminescence intensity of the free LUC-enzymes (violet) as a function
of time. Autoclaved water was used as a blank (green). The maximum intensity of
the free LUC-enzymes was normalized to 1.
5.2 Analyzing DNA origamis
The concentrations of the DNA origamis were determined using BioTek Eon Mi-
croplate UV/VIS Spectrophotometer. DNA origami concentrations (cDNA) were
estimated using Beer-Lambert relation,
A260 = ε260cDNAl, (1)
where A260 is the absorbance at 260 nm wavelength, ε260 is the approximated
extinction coefficient (0.9 ∗ 108 M−1 cm−1 [67]) and l is the length of the light path
in centimeters (0.05 cm).
The quality of folding and purification of the DNA origami units were verified by
agarose gel electrophoresis using BIO-RAD Power Pac Basic equipment. Agarose gel
electrophoresis is a widely used method for separating DNA by size. In electrophoresis,
an applied electrical field moves the negatively charged DNA toward a positive
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electrode through an agarose gel matrix. 2 % agarose gel was prepared by dissolving
2 g of agarose (from Sigma-Aldrich) into 100 ml of 1 x TAE buffer containing 11 mM
Mg2+. The solution was stained with 80 µl of ethidium bromide (EthBr) solution
(0.625 mg/l). The binding of EthBr to DNA intensifies the fluorescent signal of
EthBr and thus enables the visualization of DNA under ultraviolet (UV) light. 1x
TAE + 11 mM Mg2+ was used as a running buffer. Samples with the volume of 10
µl were stained with 2 µl of loading dye (6 X Blue Loading Dye from New England
Biolabs). Since the spin-filtering process removes almost all the Mg2+ ions from the
DNA origami solution [106], Mg2+ concentration of the filtered samples was increased
to the same value as in the folding conditions that is about 20 mM. 10 µl of the
sample solution was pipetted into the agarose gel wells. An M13mp18 scaffold strand
was used as a reference sample containing 4 µl of M13mp18 scaffold strand, 6 µl of
filtration buffer and 2 µl of loading dye. The gels were run with a constant voltage
of 90 V for 45 minutes. The gel was visualized by ultraviolet light using BIO-RAD
Gel DocTM EZ Imager.
The origamis were also imaged by TEM to verify the correct folding. TEM images
were taken with Tecnai 12 Bio Twin instrument. The samples were prepared on
Formvar carbon coated copper grids (Electron Microscopy Sciences). A 3 µl drop
of the sample solution was placed on the grid and blotted away with a piece of
filter paper. The samples were negatively stained twice with 0.5 % uranyl acetate in
Milli-Q water.
5.3 Preparation of LUC-origami-polymer complexes
The origami-enzyme complexes (LUC-origamis) and free luciferase enzymes were
coated with varying amounts of three different cationic block-copolymers to control
enzyme reaction rates in a bioluminescence assay. The used polymer coatings included
poly(2-dimethylamino)ethyl methacrylate (PDMAEMA) homopolymer (HP) and two
different block-copolymer structures PDMAEMA-PEG (AB-type) diblock copolymer
and PDMAEMA-PEG-PDMAEMA (ABA-type) triblock copolymer. These cationic
polymers bind electrostatically to negatively charged DNA origamis. The structural
formulas of the polymers are presented in Figure 20. Further information about the
synthesis and properties of these polymers can be found in the reference [107]. Kiviaho
et al. [107] explored the electrostatic binding between these polymers and a brick-like
DNA origami. The biocompatibility of these polymers was also investigated. The
biocompatibility of PDMAEMA could be enhanced by incorporating poly(ethylene
glycol) (PEG) into the PDMAEMA. Cationic polymers, such as PDMAEMA, could
be possible used to improve the cell transfection of DNA origamis.
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Figure 20: The structural formulas of homopolymer PDMAEMA, diblock copolymer
PDMAEMA-PEG and triblock copolymer PDMAEMA-PEG-PDMAEMA. [107]
In this experiment, the LUC-origamis were filtered by the same method as
mentioned earlier but HEPES-NaOH (6.5 mM HEPES, pH 6.8) was used as a
filtration buffer in all rounds. The polymers dissolved in the HEPES/NaOH buffer
were added in 10×, 100× and 1000× excess amounts to the LUC-origamis and mixed
with the buffer so that the final concentration of the origamis in each sample was 35
nM. A LUC-origami sample without polymer coating was also prepared with the
same concentration. A control assay was prepared by titrating free LUC-enzymes,
which were diluted with HEPES-NaOH buffer, to correspond the behavior of LUC-
origami samples without added polymers (similar decay kinetics and parameters in
bioluminescence assay). The free LUC-enzymes were treated with polymers exactly
the same method as the LUC-origami samples. The samples were incubated for 2 h.
After the incubation, the activity of the enzymes was analyzed by the bioluminescence
assay described in Chapter 6.1.
5.4 Cell culture and treatment with LUC-origami complexes
Cell transfection was performed for the fully characterized and tested LUC-origami,
bare origami and free LUC-enzyme samples. In addition, the components of the
DNA origami, including short DNA strands, i.e. staples and a long scaffold strand,
were used as controls. The samples were transfected into human embryonic kidney
cells (HEK293 cells) from ATCC. HEK cells were maintained in growth media
containing Dulbecco’s modified Eagle’s medium (DMEM) with high glucose (4.5
g/l), L-glutamine (4.0 mM), sodium pyruvate (4.0 mM), glutamine and penicillin
streptomycin mix (from HyClone-Thermo Scientific), supplemented with 10 % (v/v)
35
fetal bovine serum (FBS) (from Gibco-Life Technologies). Cells were maintained at
37 ◦C in a humidified (5 % CO2) incubator.
1 µg of each sample was transfected into HEK cells transiently with or without a
transfection reagent polyethylenimine (PEI) (25 kDa, linear, from Polysciences #
23966-2). PEI is a cationic polymer that attaches to DNA and turns it into positively
charged particles that bind to anionic cell surfaces. The concentrations of transfected
LUC-origami and bare origami were approximately 1 nM. The concentration of the
free luciferase sample (LUC (adjusted)) was titrated to match the luminescence decay
curve of LUC-origami sample shown in Chapter 6.2.1. The cells were then let grow
at 37 ◦C for 12-36 h to allow the DNA origami transfection. After the transfection,
the cells were fixed in 4 % paraformaldehyde (PFA) and washed three times with
phosphate-buffered saline (PBS) in order to remove all the added origamis and other
molecules that are left on the surface of the cells or the cell culturing plates. Cells
were lysed using coelenterazine-based substrate 12 h after the transfection and the
bioluminescence assay was immediately performed.
In addition, the DNA origamis were labeled with fluorescent Cy3 dyes in order
to detect the transfection by confocal microscopy. The HEK293 cell nuclei was
labeled with DAPI (Sigma Aldrich) nucleic acid stain. Fluorescent labeling enables
the detection of target molecules, since fluorescent molecules respond distinctly to
light compared to other molecules. In confocal microscopy, images are taken from
different focal planes through samples and then combined to form a stack. Confocal
microscopy images were taken with Leica TCS SP8 microscopy (405 nm violet blue
diode laser and 514 nm argon blue laser) using a 63X objective (HC PL APO CS2
with glycerol).
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6 Results and discussion
This section is divided into two subsections in order to distinguish the activity
measurements of the LUC-origami-polymer complexes from the methods to verify the
delivery of LUC-enzymes into the cells. But first, the results from the characterization
of the LUC-origami complexes are presented.
The DNA origami nanocarriers were characterized by transmission electron
microscope and agarose gel electrophoresis, as shown in Figure 21. The designed model
of origamis corresponded the structure of folded DNA origamis as can be seen from
TEM images. Moreover, agarose gel electrophoresis confirmed the efficient purification
of the origamis from the excess staple strands. In agarose gel electrophoresis figure,
the left sample named S signifies M13mp18 scaffold strand that was used as a
reference. Folded HTB signifies DNA origamis right after folding, and filtered HTB
signifies filtered DNA origamis. The excess staple strands in the folded HTB sample
correspond the lowest bright band in the folded HTB column. Because of the small
size of staple strands, they move faster in the gel than the origami itself. HTB
origamis loaded with luciferase enzymes (LUC+HTB) were also analyzed by gel
electrophoresis. The binding of the LUC-enzymes greatly affected the running speed
of the origami. LUC-enzymes seem to bind efficiently and also nonspecifically to
origamis, since the origami band totally disappeared in the gel. Due to the nonspecific
binding of Streptavidin-Lucia enzymes with an isoelectric point (pl) of 5.8, the charge
of the LUC+HTB sample may be highly negative in the filtration buffer (pH 8.57).
This may cause the origamis to shift faster towards the positive side of the gel.
Figure 21: The designed model and TEM images of the DNA origami. Agarose gel
electrophoresis of the DNA origamis (folded and filtered HTB) and the origamis
loaded with LUC-enzymes (LUC+HTB). Agarose gel electrophoresis showed efficient
purification of origamis (HTB) from excess staple strands that correspond the lowest
bright band in the folded HTB column. A M13mp18 scaffold strand was used as a
reference (S). [104]
As the enzymes were found to bind to DNA origamis also nonspecifically, the
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real enzyme concentration is much more than three times the origami concentration.
The origami tube contained three binding sites for LUC-enzyme. Because of the
nonspecific binding, the real enzyme concentration in origami samples was hard to
control and measure. In the following experiments, the free enzyme concentration
was titrated to match the behavior of the origami sample with enzymes attached
(LUC-origami).
6.1 The activity measurements of LUC-origami-polymer com-
plexes
The polymer coated LUC-origamis were analyzed by the bioluminescence assay to
study the effect of the coatings on the enzyme activity. The used polymer coatings
included homopolymer (HP) PDMAEMA, diblock copolymer (AB) PDMAEMA-
PEG and triblock copolymer (ABA) PDMAEMA-PEG-PDMAEMA in 10×, 100×
and 1000× excess concentrations with respect to DNA origami. The bioluminescence
assay was measured as a function of time by mixing 10 µl of polymer coated LUC-
origamis with ready 50 µl of coelenterazine-based luminescence assay reagent. The
bare LUC-origami sample that did not contain polymers was also analyzed, and as a
blank 10 µl of HEPES/NaOH buffer (pH 6.8) was used. The reagent was mixed with
all of the samples at the same time, and the measurement started 10 seconds after
adding the assay reagent to the origami solutions. The control assay, only enzymes
and polymers, was performed exactly at the same method. The luminescence decay
for the samples obeys a standard stretched exponential behaviour [108]
I(t) = A exp[−(t/T )β], (2)
where I = luminescence intensity, A = constant, T = time constant of the reaction
and β = stretching exponent (0 <β ≤ 1). The luminescence assays were analyzed
using the above-mentioned equation (2). The example of the normalized decay assay
(A = 1) and the fits for the HP coated LUC-origamis can be seen in Figure 22A.
Time constants from the fits for all the origami-polymer complexes (HP, AB and
ABA-coated) are shown in Figures 22B, 22C and 22D. The fitting parameters A and
T for all the samples are presented in Table 3. The curves were fitted to data points
using MATLAB.
LUC-enzymes showed appropriate catalytic activity in all samples indicating that
the added polymer is not capable of blocking the enzyme activity completely. All the
samples showed stretched behavior in the decay kinetics (β is 0.7-0.9). The polymer
coatings seem to change the enzyme activity for LUC-origami, in other words they
seem to affect the reaction rates of the enzymes in the origami samples. Instead,
the polymer coated LUC-enzymes did not show any change in their behavior when
increasing the amount of polymers. As can be seen from Table 3, the characteristic
reaction time constant (T ) was gradually prolonged for LUC-origamis but not for
the free enzymes when the amount of polymers was increased. The prolongation
was the most significant for the LUC-origami coated with homopolymer and with
AB-type block-copolymer in 1000× excess amount, as these thickest coatings resulted
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in about 2 times greater T value compared with the bare LUC-origamis (no polymer).
The change in T value for AB-type polymer was not as significant as it was for
homopolymer. T values for ABA-type polymer remained almost the same in all
polymer concentrations. The results indicate that the observed prolongation resulted
from the attachment of LUC-enzymes to origamis. One explanation for this might
be that the polymer coating of the origami limits the accessibility of the enzymes
and restricts the diffusion rate of the substrate [107].
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Figure 22: A) Normalized luminescence decay data points and fitted curves for
bare LUC-origami sample (red) and for LUC-origami coated with PDMAEMA
homopolymer (HP) 100× (blue) and 1000× (green) excess amounts. 10× excess
amount of HP was omitted for clarity because it follows the same decay as that of
LUC-origami + 100× HP. The curves were fitted using the stretched exponential
equation (2). B)-D) Fitted normalized time constants of the luminescence decay for
LUC-origami (blue) and free LUC enzymes (control assay without origamis, green)
complexed with HP, AB and ABA, respectively. Time constants were determined
with four different polymer concentrations (0×, 10×, 100× and 1000× with respect
to DNA origami). Each case without added polymer has been normalized to 1. [107]
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Table 3: Fitted normalized time constants T and the stretching exponents β for all
the LUC-origami and free LUC samples used in the bioluminescence assay. The
similar amount of enzyme is added to each sample.
Polymer LUC-origami Free LUC
(amount/
DNA origami)
No polymer T = 1 ± 0.1 (normalized) T = 1 ± 0.1 (normalized)
β = 0.81 ± 0.02 β = 0.85 ± 0.07
HP (10x) T = 1.0 ± 0.1, β = 0.84 ± 0.03 T = 1.0 ± 0.1, β = 0.85 ± 0.05
HP (100x) T = 1.1 ± 0.1, β = 0.83 ± 0.03 T = 1.0 ± 0.1, β = 0.85 ± 0.05
HP (1000x) T = 2.1 ± 0.6, β = 0.87 ± 0.03 T = 1.0 ± 0.1, β = 0.85 ± 0.05
AB (10x) T = 1.6 ± 0.2, β = 0.85 ± 0.03 T = 1.0 ± 0.1, β = 0.85 ± 0.05
AB (100x) T = 1.6 ± 0.3, β = 0.76 ± 0.07 T = 1.0 ± 0.1, β = 0.85 ± 0.05
AB (1000x) T = 2.0 ± 0.2, β = 0.80 ± 0.07 T = 1.0 ± 0.1, β = 0.85 ± 0.05
ABA (10x) T = 1.6 ± 0.2, β = 0.73 ± 0.04 T = 1.0 ± 0.1, β = 0.85 ± 0.05
ABA (100x) T = 1.8 ± 0.2, β = 0.79 ± 0.03 T = 1.0 ± 0.1, β = 0.85 ± 0.05
ABA (1000x) T = 1.7 ± 0.1, β = 0.81 ± 0.07 T = 1.0 ± 0.1, β = 0.85 ± 0.05
6.2 Determination of the delivery of LUC-origami complexes
into cells
After the characterization of LUC-origami complexes, the bioluminescence assay was
performed to verify the proper enzyme activity in the LUC-origami sample. After
this, the LUC-origamis were transfected into the cells, and the transfection was then
examined by confocal microscopy and bioluminescence assay.
6.2.1 Cell-free bioluminescence assay
The bioluminescence intensity for the spin-filtered LUC-origami (LUC+HTB), free
LUC-enzyme and bare origami (HTB) were analyzed. The bioluminescence intensity
of the samples was measured similarly as explained in previous sections. The
luminescence decay curves and the relative luminescence intensities of the samples
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are shown in Figure 23. The concentration of the free enzyme sample was titrated
to match the luminescence decay curve of the LUC+HTB sample. Typically the
concentration of adjusted free luciferase was 500–800 nM, i.e. 8–20 times the origami
concentration (35–100 nM). LUC-origami samples might have contained a modest
amount of enzymes that were not removed in the spin-filtering process, see Appendix
B. In addition, it seems that all the added enzymes remained nonspecifically bound
to origamis after purification. The concentrations of LUC-origami samples were
calculated using the equation (1). The luminescence decay for the LUC-origami and
the free LUC-enzyme corresponded the typical decay for the luciferase enzyme (100
µg/ml) shown in Figure 19. The bare origami did not show any activity.
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Figure 23: The luminescence decay for the LUC-origamis (LUC+HTB), the free
enzymes (LUC adjusted) and the bare origamis (HTB) as a function of time. The
maximum luminescence intensity for the LUC+HTB (violet) sample was normalized
to 1 and it was compared to the maximum intensity of the LUC (green) and HTB
(blue) samples. The mean values were calculated from three different measurements.
[104]
6.2.2 Confocal microscopy
After the transfection experiments described in Chapter 5.4, the confocal microscopy
images were taken to verify the proper transfection of DNA origamis. After 36 h
of transfection, it seems that the origamis were co-localized with the cell nuclei as
can be seen in Figure 24a-c. Cy3-labeled DNA origamis (red) overlay DAPI-labeled
HEK293 cell nuclei (blue) as shown in Figure 24c. This suggests that the origami
was successfully transfected into the cells. On the other hand, it might be possible
that some of the origamis were only attached on the surface of the cell membrane.
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In addition, the degradation of origamis in cell culture media was not studied in this
thesis, and thus it might be possible that only the components of the origami were
entered into the cells. In order to examine the transfection further, the activity of
the delivered LUC was measured in the cell lysates using bioluminescence assay.
a b c
Figure 24: (a)-(c) Confocal microscopy images of DNA origami transfection. (a)
DAPI-labeled HEK293 cell nuclei. (b) Cy3-labeled DNA origamis. (c) Overlay of
the figures (a) and (b). [104]
6.2.3 Bioluminescence assay from cell lysates
The enzyme activity was detected from cell lysates after 12 h of transfection using the
bioluminescence assay similarly as explained in Chapter 6.2.1. The luminescence decay
for each sample was significantly slower when measured from cell lysates than from the
HEPES/NaOH buffer (cell-free luminescence assay). In addition, the luminescence
level of the transfected samples stayed the same over 10–15 minutes. This was mainly
due to the dilution of the samples during the transfection experiments. Moreover,
the luminescence intensity might have been affected by cellular compartments.
Figure 25 shows the normalized maximum luminescence intensities for all the
samples transfected with or without PEI. Duplicate or triplicate samples was used to
determine each measurement point in every measurement. Two left-side histograms
show the luminescence intensity of transfected unfiltered LUC-origami (LUC+HTB),
LUC+staples, LUC+scaffold and free LUC samples. The HTB was spin-filtered after
folding, but not after the LUC has been added. Exactly the same amount of LUC
was added to each sample. The LUC+HTB sample showed greatest luminescence
intensity and the free LUC sample the slowest when the PEI was used as a transfection
reagent. The luminescence intensity was slightly increased for the staples+LUC
and scaffold+LUC samples in the experiment without PEI and the staples+LUC
sample showed the greatest activity. This suggest that the components of the origami
assist in transfection. However, the LUC-origami seems to enter cells better than the
LUC+staples and LUC+scaffold when PEI is included. Two right-side histograms
show the luminescence intensity for the filtered LUC-origami (LUC-HTB), free LUC
and bare origami (HTB). The results suggest that the origami entered cells better
than the free LUC, as the filtered HTB+LUC sample possessed roughly 3 times as
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high intensity as the free LUC. Both samples contained the same amount of LUC,
since the concentration of the free LUC was titrated to match the decay kinetics of
LUC+HTB before transfection. In addition, it seems that the samples were able to
enter cells without a transfection reagent.
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Figure 25: Normalized maximum luminescence intensities for the unfiltered LUC-
HTB, staples+LUC, scaffold+LUC and free LUC, and for the spin-filtered HTB+LUC,
free LUC and bare HTB with or without PEI. The bioluminescence intensities were
measured from cell lysates after 12 h of transfection. The highest value in each
measurement is normalized to 1. [104]
The effect of the nonspecific binding between LUC and HTB was studied further
by fabricating a DNA origami that did not contain biotinylated binding sites (HT)
for comparison. The HT sample was treated similarly as the HTB sample, and the
same amount of luciferase enzyme was added to both of the samples. Spin-filtered
LUC+HTB and LUC+HT were transfected to the cells (500 pM concentrations)
and the bioluminescence assay was performed after 48 h of transfection from the
cell lysates similarly as described earlier. The results are not directly comparable to
other transfection results, since the samples were incubated for 48 h and not for 12 h.
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Figure 26 shows the normalized maximum luminescence intensity for the LUC-HTB
and LUC-HT samples. The LUC-HTB sample showed greater activity than the
LUC-HT sample. The activity of HT sample was about 20 % of LUC+HTB signal,
indicating that LUC can bind unspecifically to the origami surface. However, when
the bioluminescence was measured from the HEPES-NaOH buffer before transfection
experiments, the enzyme activity was the same for LUC+HTB and LUC+HT samples.
One explanation for this might be that the methods used in transfection experiments
might have removed the majority of nonspecifically bound LUC-enzymes but not
the LUC-enzymes that are bound via strong biotin-streptavidin interaction. Overall,
the used method could be considered rather feasible, since the lowest DNA origami
working concentrations were approximately 500 pM - 1 nM.
Figure 26: Normalized maximum luminescence intensity for the LUC-origami with
biotinylated binding sites (LUC-HTB) and without biotinylated binding sites (LUC-
HT) measured from the cell lysates after 48 h of transfection.
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7 Conclusions
The aim of this thesis was to utilize a tubular DNA origami nanocarrier to deliver
enzymes into cells. The delivered enzyme was streptavidin functionalized Lucia
luciferase (LUC) that was detected by a bioluminescence assay and the transfection
was also studied by a confocal microscopy. The results suggest that the DNA origami
could be used for delivering enzymes into cells, and that the enzymes can remain
active after transfection. Moreover, it seems that a tubular DNA origami can be
transfected into cells without the transfection reagent. However, the components of
the origami seemed to assist in transfection, and therefore the shape of the origami
might not have contributed to the transfection. In addition, the integrity and
stability of the DNA origamis should be studied further to prove the successful use
of these DNA origamis as delivery vehicles. The structure of nanotubes should be
characterized by TEM after adding the LUC-enzymes and the transfection reagent
PEI to verify that the DNA origamis are stayed intact. The cytotoxicity of PEI to cell
viability should be examined for PEI-mediated uptake experiments. Moreover, the
cell uptake experiments for confocal microscopy were run over 36 h which is quite a
long incubation time. The confocal images should be taken after 12 h and the possible
degradation of the DNA origamis in cell culture media must be investigated carefully.
Furthermore, the enzymes could be labeled fluorescently in order to investigate the
co-localization of the enzymes and the origamis in cells. These examinations were
not done in this thesis due to limited schedule.
Another target of this thesis was to examine the enzyme activity of polymer coated
DNA origamis loaded with LUC-enzymes. The findings suggest that by adjusting
the amount of cationic polymers that coat the DNA origamis, it could be possible to
control the enzyme kinetics of the complexes. The thickest polymer coatings seemed
to prolong the reaction rates of the enzyme reactions. In future experiments the
cytotoxicity of the complexes should be studied to verify their suitability for cellular
environments. Such a polymer coated origami system could also be possibly utilized
to protect the molecular cargo attached to origamis.
One obstacle in this thesis arose from the fact that the proposed origami was not
able to spatially organize the enzymes. The DNA origamis contained three biotiny-
lated binding sites for the attachment of the LUC-enzymes, however it was noticed
that the enzymes most likely attached to the origamis nonspecifically. Therefore, it
was difficult to determine the real enzyme concentration of the samples. In order
to utilize the same amount of enzymes in the control samples (free LUC-enzymes),
the concentration of the free LUC samples was titrated to match the decay kinetics
of LUC-origami samples. Additional experiments should be performed to limit the
nonspecific binding. One approach is to reduce the ionic interaction between the
enzyme and the origami by modifying the salt concentration. Another approach is
to vary the pH to change the charge of the enzyme.
The successful cellular delivery of enzymes is important in various therapeutic
applications. Recent study [5] showed that enzymes coated by DNA strands can be
delivered into cells and retain their activity in cells. DNA origami nanocarriers could
enable further specified cell targeting due to the possibility of modifications and the
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modularity of DNA origamis. Moreover, it has been shown that the encapsulation
of enzymes using DNA origami could protect them against protease digestion [109].
However, the proposed origami carrier in this thesis cannot accomplish these properties
because of the nonspecific binding of the enzymes. If the problems related to
nonspecific binding can be resolved, future works could include encapsulation of the
origami system by virus capsid proteins, which has shown to improve the delivery of
origamis into cells [34]. In addition, it would be interesting to examine the effect of
the polymer coatings on the transfection rates of DNA origamis.
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A Strands for DNA origami
The complete set of the staple strands for DNA origami are listed below. More
information is available from the Ref. [93].
Biotinylated strands for HTB (3 strands):
Sequence (5’ -> 3’) Bases
Biotin-AAACATTAAATTTTGCTCCAACACGTTG 28
Biotin-AGCTTTCAACATTAAATAGTGAATTTGCCAGAATGATTGAC 41
Biotin-ACGAGGCAATTCCAACGAAACGCAAAGACGTTCAGCTA 38
Non-biotinylated strands for HT, optional, replaces the above-mentioned strands (3
strands):
Sequence (5’ -> 3’) Bases
AAACATTAAATTTTGCTCCAACACGTTG 28
AGCTTTCAACATTAAATAGTGAATTTGCCAGAATGATTGAC 41
ACGAGGCAATTCCAACGAAACGCAAAGACGTTCAGCTA 38
Cy3-labeled fluorescent strand, optional (1 strand):
Sequence (5’ -> 3’) Bases
Cy3-GGGAAAGGAGAAAAAA 16
Binding sites for the Cy3-labeled strand (5 strands):
Sequence (5’ -> 3’) Bases
CAACTAATCATAACCAGACGACTGGATAGCGTTTTTTTCT-
CCTTTCCC 48
TGGTCAGTACAGTTGACAGGTCAGTTTTTTCTCCTTTCCC 40
CCAAGCGGCCTGATGAAATCCTGAAAGAGGACATTTTTT-
CTCCTTTCCC 49
GAATACGAAACCGGATAGCCAAGCCCTTTTTAAGAATTTT-
TTCTCCTTTCCC 52
AAGCTTGAATCATGGTTTTTTTCTCCTTTCCC 32
Core strands (91 strands):
Sequence (5’ -> 3’) Bases
CGTAATACATCAACATCTGGCC 22
AGGCAATGCAGCTGATTGCCTTAAACGGGCCTAAAAA-
GGCGTTGCTTATC 50
CAATCCAATTTATTTACTCATCCAACATATAAAAGAGCA-
TGTAAAACCAA 50
TATATTTAGGATAAATGACCCAAGAATT 28
TTTCACCGCAGCAACCGCGAAAGAC 25
56
AATTCGGAAAAGCCCTATAGCCCGGAAAATATAATCAA-
TTGATA 44
GAGCTGCTCAGAGAAAATACGTGAGGC 27
AATATGATACAAACTACAAGGTTTCAGGCCACCCTTCT-
AGGTGT 44
TAGTAAATTTCAACCCGAACCTCAA 25
AATTCACAGAGCCCTGACTATTATAATTATGTA 33
CGCGAGATCTTCTATAAGAACTGTTT 26
CAGCACCTTTTCATGGAAGGGCGCCAT 27
AATGCTTATAAATAAGTAAAATAACGGA 28
TTTCAGAAGATAAAACAGAGCGAACGAATATACGTGG 37
TCAATCACAGGTCAAGAACCGGATAGCA 28
TTGCCCTGACGATAATCATCTAAAGAA 27
CGATTAAGTTGGTGACCTTCAAAAGCTGGCGTTAAGA-
CCTAA 42
ATCATTTTATCAGTTTGGATACGTAAATTTAACG 34
GAAATACGCATTTTCGAACCAGACAGCCAGGTTTGAGG 38
TGTTACTTGGGAACCTAGGCTGGCGTAACGCCAGGG 36
CTTGCTAAAAAAAAGTAGGATGGCTTAGA 29
CACAGACAATAGCCATTACATGGAA 25
TCACCCTCAGCAGAAATCGGCAACATTAGACG 32
TTGAAAACTCTGAGAAGGAGGTTGAAATCAAAATCAT-
AGGATAGCGATAG 50
TTCCTGTAGTTACGAGGCATAAATAGCG 28
CGCCATTCGATCGGAAAGGGGACGTTGTGCAGGTCC-
GATTGACAAAGAC 49
GAAGCGTTGAGTTAAGCAATAGACGCTGGAGGGTGG 36
AGCCCAATCACCAGTATTCAAAAAGGGT 28
GGTCATTTTTGCGAACCCTCAGAGAAAGGCGGAGTG-
TCTTTCCAGACGT 49
ATCGGTTATAAAGCAAAAGGTTTAAAGGCCGCTGTTT-
AGCTATGGGGCGC 50
TGTGATGAAACCATAGCAAGCGCCATAGCATTTT 34
CTTAGATTGAGTGAATAATTTTCGTTGGGTCAATCG 36
GTACCGCTCATCGTAGGAATCCTATTATTTATCC 34
ATCACCGTACTCCACCCTCTTGCCTGGAGATCTACA-
AAGGCTGTCAGAAG 50
ACATGACATTCAACGACTCTAGAGGAAGACGGTCAA-
TAAACA 42
AAGGTGGGAGAACACTTTCCAGAATCGG 28
GGCAGAGTTTAACAACGCCAAAGCACCAAGTCACG-
GATGTGCTGCAAGG 49
ACAGTCAAAGCGAAAAACAACTGAATTTTCTGTATG-
GGAAGG 42
TAATTGCTATAATGAAGTACGGTGTCTAAAGCTAAG-
CTTAATCATCAC 48
57
TACATTTGACGCCTGTAGCATTCCACAGTTTTGTC 35
AACGATTACCAGAAGCCAAAAGAACTGCAAGCCG-
TTATAAGA 42
TATCGGTGAATTACCAAATCTAGGCTTAGCCTTAG-
AATCC 40
TTCGCGTTAATGCCCCAGAGGAGAGGCTTTTGCA-
AAACATTAAATTT 47
CACCCTAGCATTGACGACTACCTTTTTCACCCTCC-
CGGAACGGTTT 46
TAAAGTGTAAACCTGTCGAAGAATACACTAACGCC-
GGAAGCA 42
CGAAAAACCGTTGGAAATACAACTGAACACCCCGT-
CAAAGGG 42
ACGCTCACTATCAAGCCATTGCTGACCT 28
TTTTTCTCCAACGCGTTTTTTGTTTAA 27
TTGAGTCACCCTCATATTTAGATTCAAATCACCATC 36
ATAACCGATACCACCAGCTTAAACAGCTTGCATCG-
CCCACGC 42
TGAAACAAACATCTGAGTAACTATTTCGGAAGGATT-
AGGATGCGTAG 47
AGTATCGTCACCAATAAATAAGCTCATTC 29
GGACGAACTAACGGAGGGATAGGTCACTCTGCCA-
CTTTCCG 41
GGTCAGTTCTAAAGTGCTGAATCCTTTTGATAAGA 35
AGTTGAGGGAAGAATTATGCGTCAACTTGAAACAC-
ACGTAAC 42
GAAAGCGTAAGAATTCGGTCGCAGGGAGGGCATCA 35
TCAGATGGAAACAATGTTTAGACGATAA 28
TAATTTTCAAACAAATATCGCGGAAGCA 28
CGAGCCAGACGACAATCATAAAGCCGGA 28
GGAGAATTCTACATTTTAACGAGCGTATAAAAACAGG 37
TTTTCCCTTACCATTCGATAG 21
ATTCTACAGCAAAATTAAGCAGTACCAA 28
CGGGCAACCAGCTGATAAACAGCCATAAGAACGCG-
CGAAAG 41
CGGTATTATTACCGGGGTATTGAAACCATCCCATC 35
CAAGACCAGAGCCGCAACCTCCCGTTAATTAGAAA-
GCGCCAAAAGGAACC 50
AGTGACAACTGTTGCGCGACCG 22
TCAAGAGAGGCGCAGAACTGAAATTCTGTATCAAC-
AATAGA 41
GCCTGTTTCCAGACGTAATAAGCTTAAT 28
GTTTTGCTCAGATATAAGCAAAAACTAGCATG 32
ATTTTCAGGACAGAAATAAAGAAATTTAGCGGG 33
GCCTAAATCAAGATCACTTCACCGCCTGCGAGGGT-
CTTTTGCGGGATCG 49
58
GGTGGTTGCGGTCCCTTTTACAGAGAGAATAACCT-
TTCCAGA 42
AAAAGGGCACCACGTGTTATCGGGTGCC 28
ATTTGACAATATATGTAAGACGCTGAGACATTTAGC-
AAAAGCACTGATTG 50
CTTTGAATACCATTTCAATCAACACTATGCAGATAC-
ATAAATTCATC 47
GAGAATAATTTTTTAAGGAGCGAGGTGAA 29
CGTCAAAACATTAATGTCGGGAAAGCCTGCGCTC-
ACGCTCCCCGGGTACC 50
ATATCAAACCTTTTGCTCCAGACCGTTTTAAGCAT-
CAAATCAGGT 45
TTGAGGACTCAATCTGAAAAA 21
CCCCGGTCCCCCTCACTTTACCACAACATT 30
CAAAATTAATTAAGAGTCTTACAGGAAAACGACGACAG 38
CAAAGCGGATTTTCGAGCAGTATTATAGATAA 32
AGCATCGGAAGCCCTGAGAGAGTTAGTGAGA 31
TCAGGCTGCGCACTCGCCACCAAGAACCGC 30
ATCAGAAGTTTTGCCCTGCCAGTGCCCGTATAAAA-
AGATGA 41
GGGTAATTTCATTGCTGATTGATGATGGC 29
GAGCTCGGTGAAATGAATAAGATACATA 28
AAACCAAGTAAGAGTACCTGAACAATTTC 29
ATGCAGAACGCCTAATTTCACAAC 24
ATTTAATCGCCTCCTGCCTCAGGAAGATCGATAAGGC 37
AAAATCTAGTTTCAGCCGGAG 21
Left core strands (20 strands):
Sequence (5’ -> 3’) Bases
CTGCGGCTGAATACATCATA 20
ATTAACAAAACATCTTTTTGAAACCCTTCAACACGACCAGT 41
AAGAAATATCATCCGAAACA 20
TATTTGCTATACTTAATCGTCTAAACAGTTCAGAAAACGA 40
AAAAGCTAAACACCAAATCACAGAACGAGTAGTAAA 36
TGCGGGAGGTTTTGAAGCCTTAATTTGCCAGTTACAAAATG-
AAAATA 47
ACTAACAACTAATAGATTAGAGCCGTCAAGACTTTAAAAAGT 42
GTTTCATCGTCATTTATTTAGAAATGGTTGAAATGG 36
CAAATCTATATAAGACGTTGATTTAGGAA 29
GACTTCAATTCGACAACT 18
ATCGGGAAATATACTCAAAAT 21
AAGTACAAAACACTCAAGAACCGCCCAATAGCAA 34
GAATGACCATAAACAAAGAACGTTAT 26
TACAATTTTATCCTGAATCTTACCAACGCTGACGCTC 37
ATACGAGGAGATTTGAATAATAATCAATAATCGGCTGT 38
59
TTCACCAGTCACAGGAAAAAATCGTCCAATAACAGCAACG 40
TGAGAATGCCGGAAACATATGCGTTATACAGTAGGGAGAA-
TATAAAGT 48
ATTAATTAACCTTGCATAAATATTACCT 28
TAAAGTCCAACTTGCGACCTGCTCCA 26
CAACTACTGTAGCCAGCAAAAATATC 26
Right core strands (15 strands):
Sequence (5’ -> 3’) Bases
TCGATGAACGGTAATCGTAAAACAGGAAGAAATATTTTT-
ATTCT 44
TAATAGTGTTGAGTGTGCTTGCTGAGTGTTCCAGTTTG-
GAACAAG 45
AGGTAAAGATTCACCGTTCTTTTTTGAAGAGTCTGGAG-
CAAACAAGAGAA 50
CGTTCCAGTAAGCGTCATACATGGCAAGAAAA 32
TGAGCGAACGGCGGGAAAGCGATAAATC 28
TAATGAGCTGCCCGAGGCATGATTAAGAAAAATACTTT-
ATTTTGT 45
AGTTTTAACGGGGTCAGTGCCTTTTTGATGATTCGCGT-
TAAATG 44
CTCATTAAGGCAGGTCAGACGATT 24
GTCATAGTAGCGCGGTAATCACACCAGTCACCGTCAC-
CGACTTGA 45
TAACCGTGCAGTTGGTGCCAGAGCCGCCGCCCAGAG-
CCTCACCGG 45
TTACCAGCGCGGGAGGGGGTGAATTATCATGTAATTTA 38
CTGAGTTTCGTAGGAACGAACCGCAGGAGGTAGGGTTG 38
GCAGCCATCTTACCGGAACAAAGCGGGGAGAGGCGGT 37
AAGAACGTGGACTCCAATGAACAAAGTCAGAGGGTAAT-
TGAGCGCTA 47
TACCAGGGAGACTCCTCAAGAGAACCTATGTTAA 34
60
B Luminescence assay for filtered and unfiltered
Streptavidin-Lucia enzyme
Figure B1 shows that the spin-filtering procedure was efficient for removing free
LUC-enzymes. The first data points are measured around 10 seconds after adding
the substrate, and thus the measured maximum intensities do not directly compare
to the actual LUC concentrations.
Figure B1: Luminescence decay and the normalized maximum luminescence intensity
for the plain free Streptavidin-Lucia (LUC) and the spin-filtered Streptavidin-Lucia
(Filtered LUC).
